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Abstract
Background: Fall-related injuries in older adults result in serious consequences to
individuals and health care system, especially with the increasing aging population. The
purpose of this study was to (1) describe medication prescription patterns within one year
prior to fall-related injuries; (2) identify medication classes prescribed within 30 days prior to
the injury that were associated to fall-related injury; and (3) examine the association between
fall-related injuries and continuous use or new initiation of most commonly prescribed
medications.
Methods: Studies used administrative health care data in Ontario. Study 1 described the
frequency of medications prescribed to older adults within one year before they had fallrelated injuries. Study 2 and 3 were case-control studies. The cases were older adults aged 66
years and older, who had a fall-related injury between January 2010 and December 2014.
Controls were older adults with same age, sex and residence area as the cases. In study 2,
medications prescribed to both groups were recorded and logistic regression was conducted
to examine the association between medications and injuries. Study 3 defined continuous use
as medication use for more than 90 days and new initiation was defined as starting a
medication within 30 days prior to injuries. Logistic regression was conducted to examine the
association between injuries and continuous use or new initiation of medications.
Results: Within one year before the injury, 27.2% of older adults were prescribed
antidepressants, 25.0% opioids, 16.6% anxiolytics, and 36.4% were prescribed 5-9
medications and 41.2% were prescribed 10 or more medications. After adjustment for sex,
age group, residence area, income and number of medications prescribed, laxatives,
antibiotics and bronchodilators were identified to increase the risk of fall-related injury.
Continuous use of antidepressants, anticholinesterases and antithrombin agents and new
initiation of antidepressants, opioids and cephalosporins were reported to increase the risk for
injuries.
Conclusion: Findings of this thesis uncovered several medication classes such as antibiotics
and bronchodilators were associated with increased risk of fall-related injury. Both,
ii

continuous use and new initiation of particular medication classes were associated with
injuries. Well-designed prospective cohort studies are needed to provide more convincing
evidence.
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Summary for Lay Audience
Fall-related injuries in older adults can result in serious harm to individuals and health care
system, especially with the world increasing aging population. The purpose of this study was
to (1) describe the types of medications older adults used within one year before they
experienced a fall that resulted in an injury; (2) identify if medications prescribed within 30
days before the fall that were associated with increased the risk of fall-related injury; and (3)
find out whether continuous use of a medication or start of a new medication were associated
with increased the risk of fall-related injury. Data was extracted from databases hosted by
IC/ES. We recorded the medication prescribed to older adults and calculate the percentage of
medication users. Our result was, within one year before the injury, 27.2% of older adults
used antidepressants, 25.0% opioids, 16.6% anxiolytics, 36.4% used 5-9 different
medications and 41.2% used 10 or more different medications. Then we used case-control
study design and logistic regression to find out the possibility of having fall-related injury
when an older adult took certain kind of medication. We also identified the possibility of
having fall-related injuries when an older adult took certain kind of medication for over 90
days or start a new medication within 30 days prior to the injury. After taking sex, age group,
residence area, income level and number of medications used into consideration, we found
that users of laxatives, antibiotics and inhaled medications for asthma were more likely to
have fall-related injury. Continuous use of antidepressants, medications for dementia and
blood thinners and new initiation of antidepressants, opioids and cephalosporins were
associated with increased risk for fall-related injuries. Findings of this thesis uncovered
several medication classes such as antibiotics and bronchodilators that were associated with
increased risk of fall-related injury, which was not reported in previous studies. It was also
suggested that continuous use and new initiation of particular medication classes were
associated with injuries. Well-designed cohort studies are needed in the future to provide
more convincing evidence.
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Chapter 1

1

Introduction
1.1

World Aging Population

Ageing is an inevitable process of living and, conventionally, it is measured by
chronological age where people who are 65 years or older are referred to as “older
adults” (Orimo et al., 2006; World Health Organization [WHO], 2020). Although the
ageing process is not homogeneous across the world due to different genetics, lifestyles,
overall health and environment, most developed countries in the world have accepted the
definition of older adults as people who are 65 years or older. In recent years, steady
progress has been made in reducing mortality in the early and middle years of life, which
led to the dramatic increase of ageing population globally. Better sanitation,
improvements in housing, education and nutrition, advances in preventive and therapeutic
medicine all contribute to a longer life expectancy (Kirkwood, 2017).
In 2019, the world population aged 65 years and older was almost 700 million (World
Bank, 2020), which constitutes 9.1% of the total population. According to WHO report,
there were 900 million people 60 years and older in 2015, but in 2050, the number is
expected to increase to 2 billion. For people who are 80 years and older, the world -wide
numbers will be increasing from 125 million in 2015 to 434 million in 2050 (WHO,
2018a). Population trends are similar in Canada and the province of Ontario. The number
of people aged 65 and over in Ontario is projected to almost double from 2.4 million
(16.9% of population) in 2018 to 4.6 million (23.4%) by 2046 (Ontario Ministry of
Finance, 2020).
An ageing world brings many opportunities as well as challenges, not only for older
adults and their families, but for the society as well. A longer life provides a chance for
pursue of new lifestyles and more contribution to families and communities. But if the
extended lifespan is dominated by chronic comorbidities, reduced mobility and declined
mental capacity, the implications of longer life for older adults and the society are rather
negative. Falls in older adults are one of the major public health concerns because falls
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can lead to loss of functional ability and independence, increased admissions or readmissions to health care facilities and hospitals, and inestimable medical and social
costs (Alexander & Hunter, 2017; Masud & Morris, 2001).

1.2

Falls and Fall-Related Injuries in Older Adults

A fall is defined by WHO as “an event which results in a person coming to rest
inadvertently on the ground or floor or other lower level” (WHO, 2018b). Nearly one
third of older adults fall every year globally (Chang et al., 2010; Tinetti et al., 2006), but
the rate of falls varied in different regions, with a prevalence of about 20% in China
(Wu & Ouyang, 2017), Japan (Tanimoto et al., 2014) and Canada (Pearson et al., 2014),
29% in US (Bergen et al., 2016) and 30-35% in European countries (National Institute of
Prevention and Health Education, 2008; Rapp et al., 2014; Sandmark et al., 2012). The
rate of falls increases with age, with nearly 50% of older adults who are 80 years and
older experiencing a fall each year (de Negreiros Cabral et al., 2013; Rubenstein &
Josephson, 2002).
Falls are the leading cause of fatal and non-fatal injury in older adults (Bergen et al.,
2016; Public Health Agency of Canada [PHAC], 2014). Falls account for 40% of all
injury-related deaths (WHO, 2007) and more than 80% of all injury-related hospital
admissions (Kannus et al., 2006; Peel et al., 2002). Between 30-50% falls result in minor
injuries, such as bruises or lacerations, while 5-10% of falls lead to serious injuries such
as fractures or traumatic brain injury (Cameron et al., 2012; Gillespie et al., 2012;
Goldacre et al., 2002; Health Quality Ontario, 2008; Masud & Morris, 2001; Rubenstein
& Josephson, 2002). An estimated 7 million older adults in US reported a fall-related
injury in 2014 (Bergen et al., 2016). In 2017, 8.4 million older adults in Western
European regions (22 countries including France, Germany, Greece, Italy, etc) sought
medical attention due to a fall-related injury, and about 54,000 older adults died of fallrelated injury (Haagsma et al., 2020). In 2009-2010, a total of 256,011 Canadian older
adults reported a fall-related injury, where 35% were fractures, 30% sprains or strains,
19% scrapes, bruises or blisters, 6% cuts or punctures, 3% dislocations, 2% concussions
and brain injury, and 5% other injury (PHAC, 2014).
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Although there is substantial of research published on “fall-related injury”, or “injurious
fall” or “fall injury”, a lack of standardized definition of a “fall-related injury” has been
reported repeatedly as a major methodological limitation, especially when comparing
outcomes of different studies (Lamb et al., 2005; Hauer et al., 2006; Schwenk et al.,
2012). Some studies used fractures, especially hip fracture, as a proxy for the fall-related
injury (Tanaka et al., 2018; Wong et al, 2020). However, this definition ignores a wide
range of injuries, such as head and internal injuries, which can also lead to serious
consequences requiring higher level of care, such as hospitalizations. The continuous
improvements in healthcare system and enhanced reliability of injury reporting systems
through administrative databases, identifying fall-related injury based on the healthcare
service use became a practical and credible way to study this topic (Campbell et al.,
1997; Elley et al., 2008; Schwenk et al., 2012). In this thesis, fall-related injury was
operationally defined as any injury caused by a fall that resulted in an admission to the
Emergency Department (ED) or hospital. Different fall-related injury types include:
superficial injuries, open wounds, fractures, dislocations, sprains or strains of joints and
ligaments, nerve injuries, blood vessels injuries and injuries to internal organs (Canadian
Institute of Health Information [CIHI], 2018a; WHO, 2019).
On an individual level, besides the immediate suffering from a fall-related injury,
common adverse consequences are fear of falling (Pereira et al., 2020), reduced quality of
life (Gill et al., 2013; Boyé et al. 2013), higher possibility of admission to long-term care
(Gill et al., 2013), prolonged hospital stays (PHAC, 2014), and increased risk of death
(Skelton & Todd, 2004; Stevens et al., 2006). On a societal level, fall-related injuries
pose a substantial economic burden to the public health care system. In 2004, the
estimated cost of fall-related injuries among Canadian older adults was more than $2
billion Canadian dollars (Scott et al., 2010). Florence and his colleagues reported that, in
2015, the estimated medical costs related to both fatal and nonfatal falls was
approximately US $50 billion US dollars. For non-fatal falls, Medicare paid $28.9 billion,
Medicaid $8.7 billion and private and other payers $12.0 billion. Overall medical
spending for fatal falls was estimated to be $754 million US dollars (Florence et al.,
2018). In 2006-2007, the direct cost of fall-related injury was estimated at $558.5 million
in New South Wales, Australia, and the cost of hospital admissions accounted for 84.6%
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of the total cost (Watson et al., 2011). The financial burden of fall-related injuries is
substantial and global.
Despite significant advances in fall and fall-related injury prevention research, increasing
implementation of fall prevention practices, and enhanced consciousness of individuals’
safety and self-protection, the trend of fall-related injuries around the world remains
unclear. Watson and Mitchell (2011) observed a hospitalization rate due to falls increased
by 1.7% each year from 1998-2008 in New South Wales, Australia, but the rate of
fractures resulting from falls declined by −0.4% and the non-fracture rate increased by
6.1% per year. In 2001-2010, a decreasing incidence was observed in the Swedish older
adults in younger age groups (65-79 years), with greater decreases in females (14.6% in
females vs 10.5% in males), while an increasing trend of hospitalized fall-related injuries
was observed in 80 years and older age group (Nilson et al., 2016), with greater increases
in males (4.3% in females vs 11.4% in males). Superficial injuries showed greater
increases than fractures in those aged 80 years and above (Nilson et al., 2016). Even after
controlling for US population growth, ED visit rates for falls continued to grow (Shankar
et al., 2017). Between 2003 and 2010, the ED visit rate for falls and fall-related injuries in
American older adults increased from 60.4 to 68.8/1,000 population. Older adults aged
75-84 years accounted for the greatest rate increase, with ED visit rates increasing from
56.2 to 82.1/1,000 population (Shankar et al., 2017). In Canada, the number of older
adults who reported a fall-related injury increased from 47.2 per 1,000 population in 2003
to 57.5 per 1,000 population in 2009/2010 (PHAC, 2014).
Due to rapid growth of aging population around the world, undesirable consequences of
fall-related injuries and complex trends in different injury types across countries, it is of
great importance to further research on fall-related injuries so that practical and
individualized fall prevention protocols could be developed and implemented efficiently.

1.2.1

Risk factors for falls and fall-related injury

Unclear trends in the older adult population and increased aging population make fallrelated injury a major health concern. Even after assuming that the falls rates for age and
gender remain constant overtime, a forecasted 55% increase in the number of older
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people between 2014 and 2030 in US, would result in 48.8 million falls and 11.9 million
injuries in 2030 (Bergen et al., 2016), unless there are effective prevention programs
implemented national wide. A thorough investigation of risk factors and mechanism of
falls and fall-related injuries is necessary for creating meaningful injury prevention
programs.
Fortunately, falling is not a normal part of aging and can be prevented at some occasions.
Although the present research is about injury, it is inevitable to reflect little deeper into
immediate cause of injury – the fall. Multiple risk factors are proved to be associated with
falls and they are categorized as biological, behavioral, environmental and socioeconomic
(WHO, 2007). Some of the risk factors are difficult to change while others are
modifiable. Biological risk factors such as age, gender, race and socioeconomic risk
factors such as low income and education levels, inadequate housing, limited access to
health and social care are non-modifiable or very difficult to change. But, there are risk
factors that are potentially modifiable, for example, physical or cognitive alteration d ue to
aging (biological), excess alcohol use, sedentary lifestyle, intake of multiple medications
(behavioral), slippery floor or stairs, insufficient lighting or uneven sidewalks
(environmental).
Fall-related injury, on the other hand, was often entangled with falls in previous studies.
Risk factors for fall-related injury have yet to be reported systematically. History of falls
(Ravindran & Kutty, 2016), psychotropic medication (Haasum & Johnell, 2017; Johnell
et al., 2017; Yu et al., 2017), anti-hypertensive agents (Shimbo et al., 2016), nutritional
condition (Sim et al., 2018), multiple chronic diseases (Cartagena et al. 2017), and
depression (Kvelde et al., 2015; Ravindran & Kutty, 2016) were among the risk factors
previously reported to be associated with fall-related injury after the age of 65. Both a fall
or fall-related injury are a result of complex interactions of risk factors requiring
multifactorial prevention strategies.
Interventions reported to be effective in lowering the risk of fall-related injuries include
physical exercise to improve balance (Hill, 2018), managing chronic diseases (Chang et
al., 2004; Cheng et al., 2018), visual impairment (Reed-Jones et al., 2011), and changing
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personal behaviors (Larsson et al., 2010). Many countries and health organizations have
declared the prevention of falls in older adults as an important health priority (Lamb et
al., 2005; Skelton & Todd, 2004; the Canadian Patient Safety Institute, 2015; WHO,
2007). It is forecasted that achieving a 20% reduction in falls between 2010 and 2035
among adults aged 65 years and older in Canada would save 4,400 lives and avoid a total
cost of $10.8 billion Canadian dollars (Parachute, 2015).

1.3

Medication Use in Older Adults

Older adults are the largest consumers of prescription medications worldwide. In US,
older adults comprised 13% of total population, but accounted for 34% of the prescription
medication use and 30% of over-the-counter medication use (National Council on Patient
information and Education, 2020). About 87% of older adults took one or more
prescription medications, and 36% took at least five medications concurrently (Qato et
al., 2016). CIHI reported that older adults made up only 17% of the total population in
Canada, but they accounted for almost 40% of all spending on prescription medications
and 55% of public drug program spending (CIHI, 2018b).
Medications play crucial role in older adults’ health by effectively treating the chronic
diseases, alleviating pain and increasing quality of life. However, physiological changes
in the aging body and polypharmacy make older adults susceptible to adverse drug
reactions (ADRs) that could lead to falls and fall-related injury.

1.3.1

Pharmacodynamics and pharmacokinetics of drugs in an
aging body

The premarketing clinical drug trials usually exclude elderly participants, thus the
pharmacokinetics (i.e., medication’s absorption, distribution, metabolism and excretion)
and pharmacodynamics (i.e., the physiologic effects of the medication) are unknown or
unclear in older adults. Research shows that drug absorption is reduced in the older adults
due to decreased gastrointestinal blood flow, loss of mucosal intestinal surface and
reduced gastric acidity (Hughes, 1998; Mangoni & Jackson, 2004). Moreover, the
weakening gastrointestinal movement and slower gastric emptying time increases the
medication absorption (Mangoni & Jackson, 2004). These are just some complex factors
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that make it difficult to evaluate the medication absorption in older adults. But there are
more.
With advancing age, the total body fat increases 18-36%, while the muscle mass
decreases by 30% (Vestal, 1997; Thürmann, 2020). These changes result in a prolonged
half-life (i.e., the time that a medication decreases to half of its starting concentration in
the body) of lipophilic drugs such as antidepressants, long-acting benzodiazepines and
antiepileptics. This means that the time medications exert their therapeutic effect and
adverse effects increases (Hammerlein et al., 1998; Thürmann, 2020). Similarly, the body
water content in older adults shrinks by 15-20% (Reeve et al., 2015), resulting in an
apparent decrease in the distribution volume of medications such as digoxin, diuretics
and lithium (Huang et al., 2012). Dosage reductions must be considered to avoid potential
toxicity of these drugs (Hammerlein et al., 1998; Cusack, 2004). The serum albumin
usually declines by 15-20% in frail or malnourished older adults (Cusack, 2004), which
increases the plasma concentration of free (unbound part to protein) or active fraction of
some medications. The effect of highly protein-bound medications, such as phenytoin,
diazepam and valproic acid, in a reduced serum albumin environment is enlarged.
Usually, there are no abnormal changes in hepatic function indexes as the body ages, but
the activity of hepatic metabolism of esterase is decreased which results in prolonged
half-lives of medications such as metoprolol, morphine and verapamil (Kinirons &
O'Mahony, 2004; Le Couteur et al., 2012). The age-related reduction in liver
parenchymal cells and a decrease of liver blood flow also affect the liver’s ability to
metabolize drugs (Kinirons & O'Mahony, 2004; Le Couteur et al., 2012). A combination
of these factors further compounds the drug clearance ability in older adults, causing drug
effect enhancement and more potential for adverse reactions.
Further, drug excretion in older adults declines due to reduced kidney mass, renal blood
flow, glomerular filtration rate and tubular secretion rate (Huang et al., 2012). Estimated
GFR can adequately represent the elimination of drugs through kidney function and the
dosage of medications can be adjusted according (Reeve et al., 2015).
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What is more, genetics, lifelong living habits and environmental factors can lead to high
heterogeneity in pharmacokinetics and pharmacodynamics of drugs among older adults
(Huang et al., 2012). It is unlikely that a frail 90-year-old man with multiple chronic
diseases and a robust, healthy 70-year-old man would have the same response to a
specific drug or dosage. The heterogeneity in later life and reduced homeostasis further
increase the complexity of managing medication therapy and ADRs in older adults.

1.3.2

Polypharmacy

Polypharmacy is defined as concurrent use of multiple medications by a patient.
However, there is no agreement or standard to the exact minimum number of medications
that define ‘polypharmacy’, and suggestions vary from 2 to 11 medications (Ferner &
Aronson, 2006; Masnoon et al., 2017). Although polypharmacy usually refers to the use
of prescribed medications, it is also necessary to consider the number of over-the-counter
and herbal supplements used by the patient.
Older adults often use multiple medications due to co-existence of several chronic
diseases (Crentsil et al., 2010). Gao and his colleagues (Gao et al., 2018) reported that
during the study period of 1991-1994 the number of older adults in England who were
taking five or more drugs concurrently was 1 in 8 (12%), but from 2008-2011, this rate
increased dramatically to nearly 1 in 2 (49.6%). In 2016, 65.7% of Canadian older adults
took five or more prescription drugs and 26.5% older adults took ten or more different
prescription drugs (CIHI, 2018b).
Although sometimes polypharmacy is deemed necessary and appropriate, it increases the
potential of drug-drug interactions and risk of ADRs (Weng et al., 2013). Polypharmacy
also leads to problems with adherence, especially when older adults have visual or
cognitive impairment (Wimmer et al., 2017). Older adults who receive care from
different physicians and specialists, and those who fill their prescriptions at different
pharmacies, can exaggerate the effect of polypharmacy by using medications with similar
therapeutic purpose or increased dosage (Kuo et al., 2014).
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Pharmacological changes of drugs in an aging body and polypharmacy predispose older
adults to an increased risk of falls, injuries, hospital admissions and diminished quality of
life (Chen et al., 2014; Chung, 2014; Huang et al., 2012; Rowe, et al., 1976; Tan et al.,
2015). Report from CIHI indicate that in 2011, one in 200 Canadian older adults was
hospitalized as a result of ADRs, and 2.8% of all hospitalizations of older adults were due
to ADRs (CIHI, 2013).

1.4

Medications and Fall-related Injury

Since 1980s, researchers began to pay attention to the association between medications
and falls. Several observational studies reported that benzodiazepines, antipsychotics
(most of them were tranquillizers), and tricyclic antidepressants were associated with
increased risk of falls and hip fracture in older adults (Davie et al., 1981; Macdonald,
1985; Ray et al., 1987; Tinetti et al., 1988). The concept that drugs might increase the
risk of falls was first proposed by Cumming and colleagues in 1991. The authors created
a list of medications that included diuretics and psychotropics (Cumming et al., 1991). In
2007, van der Velde and colleagues presented a list of drugs associated with increased
risk of falls according to previous studies, and it was the first time the acronym FRID for
fall risk-increasing drugs was used (van der Velde et al., 2007). The National Board of
Health and Welfare (NBHW) in Sweden produced an updated FRID list in 2010, and an
additional list of medications that cause or worsen orthostatic blood pressure, known as a
relevant fall risk factor (the Swedish NBHW, 2010). This FRIDs list used Anatomical
Therapeutic Chemical (ATC) codes proposed by WHO to id entify medication classes
(Appendix A). Although there is no consensus on which medications should be included
in FRID list, most studies recognize psychotropic medications such as opioids (N02A),
antiepileptics (N05A), anxiolytics (N05B), hypnotics and sedatives (N05C) and
antidepressants (N06A) as FRIDs (Axmon et al., 2018; Winter et al., 2016; Zia et al.,
2017).
FRIDs are important independent risk factors for both falls and fall-related injury and had
been studied extensively. Psychotropic medications can be defined as a class of drugs that
can cross the blood-brain barrier and act directly on the central nervous system (CNS)
(Bloch et al., 2010; Hill & Wee, 2012; Kawakami et al., 2019). Common psychotropic
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drugs include antiepileptics, anti-Parkinson agents, anxiolytics, hypnotics, antipsychotics,
antidepressants and drugs used in dementia. A substantial proportion of older adults use
one or more psychotropic drugs, from 20% of community-dwelling older adults (Du et
al., 2017; Préville et al., 2001) to nearly 80% of older adults lived in long-term care
facilities (Galik & Resnick, 2013; Mann et al., 2009). A series of systematic reviews
conducted in 2018 summarized the association between common medication classes and
falls, fall-related injuries, and recurrent falls in older adults (de Vries et al., 2018;
Seppala, Wermelink, et al., 2018; Seppala, van de Glind, et al., 2018). Older adults using
opioids were 78% more likely to have a fall-related injury (five-study pooled adjusted
OR [aOR]=1.78, 95%CI [1.54-2.06]; I 2 =85%). Antidepressants were associated with
increasing the risk of fall-related injury by 72% (five-study pooled aOR=1.72, 95%CI
[1.51-1.95], I 2 =72%). Benzodiazepines were associated with increasing the risk of fallrelated injury by 70% (one study reported aOR=1.70, 95%CI [1.03-2.81]). Older adults
who used antiepileptics were 43% more likely to have a fall-related injury (two-study
pooled aOR=1.43, 95%CI [1.10-1.86], I 2 =0%).
Hypertension is a very common chronic disease in older adults, with prevalence of 27%
in people younger than 60 years and 74% in those older than 80 years (Lloyd-Jones et al.,
2005). Antihypertensive drugs are among the most frequently prescribed medications in
older adults. Canadian Institute for Health Information reported that in 2016, 24.5% of
Canadian older adults were prescribed angiotensin-converting enzyme inhibitors
(ACEIs), 23.5% were prescribed beta-blocking agents (BBs), 21.9% dihydropyridine
calcium channel blockers (CCBs) and 15.7% angiotensin II antagonists (CIHI, 2018b).
Another study of 4,961 older adults with hypertension showed that 56.6% were
prescribed renin-angiotensin system (RAS) blockers, 54.2% diuretics, 45.9% BBs, and
34.2% CCBs.
Although antihypertensive drugs were not classified as FRIDs, their association with falls
and fall-related injuries in older adults was studied extensively. Diuretics (C03), BBs
(C07), CCBs (C08), and RAS inhibitors (C09) are all listed as drugs that may cause or
worsen orthostatic hypotension in the list produced by Swedish NBHW.
Antihypertensive drugs can potentially result in fall-related injury, due to syncope or
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dizziness caused by orthostatic hypotension. However, results of previous studies on
antihypertensive drugs and fall-related injuries are conflicting. Leipzig and his colleagues
completed a meta-analysis on the effect of diuretics (Leipzig et al., 1999). They reported
that furosemide and thiazides were weak risk factors for fall injuries in older adults
(pooled OR=1.08; 95%CI [1.02-1.16]), while CCBs and ACEIs were not risk factors.
Another systematic review and meta-analysis conducted by Wiens et al. (2006) suggested
a lower risk of fractures in older adults using BBs and diuretics (pooled RR=0.86 95%CI
[0.81-0.92] for diuretics and pooled RR=0.81, 95%CI [0.73-0.89] for BBs), but an
enhanced risk of fractures in older adults using CCBs (pooled RR=1.96; 95%CI [1.163.30]). For the past forty years, psychotropic medications have been consistently and
clearly recognized as FRIDs, while the evidence that antihypertensives are also FRIDs
was less clear. Overall, research had been mainly focused on psychotropic medications
and antihypertensives’ association with falls and fall-related injuries.

1.5

Background Summary and Knowledge Gap

As described, risks for falls are multifactorial. However, research has not produced strong
evidence on risk factors for fall-related injuries for older adults. Some studies focused on
specific groups of older adults such as those with vestibular dysfunction (Marchetti,
2003), or with chronic kidney disease (Kistler et al., 2018), or with lower limb
amputations (Wong et al., 2016). Other studies focused on specific settings, such as
hospitals (Fischer et al., 2005), or particular racial group, such as Chinese (Pi et al., 2016;
Li et al., 2016), Korean (Kim et al., 2018) and Indonesian (Pengpid &Peltzer, 2018).
Majority of studies reporting the risk factors for fall-related injuries in older adults are
combined with risk factors for falls. Fall-related injuries lead to high morbidity and
mortality (McClure et al., 2008), thus it is necessary to study injuries caused by falls
independently to gather evidence and inform strategies for injury prevention.
Research on medication use in older adults either focused on older adults in general
(CIHI, 2018b; Neoh et al., 2017), or on one or two specific classes of medication
frequently used by older adults such as antihypertensive drugs (Mohd et al., 2012), blood
sugar lowering drugs (Clemens et al., 2015), sedatives and hypnotics (Kassam et al.,
2006; Tseng et al., 2018), and opioids (Weesie et al., 2020; Wilder-Smith, 2005). A
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literature review by Peng and colleagues (2019) revealed the need for a comprehensive,
population-based report on medication use in older adults before they had a fall-related
injury. It is clear that more knowledge on medication use prior to injury is necessary.
Logical first step is a descriptive study to determine the patterns and prevalence of
medication prescribing to older adults before fall-related injury. This study will serve to
generate future research questions on the association between fall-related injury and
types, numbers and duration of medication use.
A clear and complete recognition of risk factors is essential in injury prevention. In 1980,
William Haddon developed of a systematic analysis for the preventative approaches with
Haddon “phase-factor” matrix (Haddon, 1980). Although it was originally designed for
traffic injuries, the matrix was soon adapted for prevention of various types of injuries,
including fall-related injuries in older adults (Sattin, 1992). Medication use was
recognized as one of the pre-event host factors for fall-related injuries in older adults and
thus the prevention focused on limiting excess prescribing of high-risk psychotropic
medications (Sattin, 1992). However, current research on association between
medications and fall-related injuries in older adults is limited and confined to
psychotropic drugs and anti-hypertensive drugs (de Vries et al., 2018; Seppala,
Wermelink, et al., 2018; Seppala, van de Glind, et al., 2018; Wiens et al., 2006; Zang,
2013), leaving out a wide range of medication classes commonly prescribed to old er
adults. For example, in developed countries, statins were prescribed to 40-50% older
adults (CIHI, 2018b; Chee et al., 2018; Ofori-Asenso et al., 2018), proton pump
inhibitors to 20-30% older adults (CIHI, 2018b; Kanno, & Moayyedi, 2019), non-steroid
anti-inflammatory drugs (NSAIDs) to 7% older adults (Wongrakpanich et al., 2018) and
insulin to 7% older adults (Clemens et al., 2015). Similarly, in 2016, 51.7% older adults
in Ontario were prescribed with statins, 32.5% proton pump inhibitors. Other medication
classes were also commonly prescribed to Ontario older adults, for example, 16.6% older
adults in Ontario were prescribed thyroid hormones, 14.4% biguanides, 14.2% penicillins
with extended spectrum, and 11.4% fluoroquinolones (CIHI, 2018b). Studies on the risk
of fall-related injury while using these medication classes are scarce and the results often
conflicting (Seppala, van de Glind, et al., 2018). Therefore, it is necessary to expand
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inquiry beyond FRIDs to include more medication classes and explore their association
with fall-related injury.

1.6

Purpose of Dissertation

The overall purpose of this dissertation was to provide a comprehensive evidence on
medication classes prescribed to older adults prior to their fall-related injuries and
evaluate their association.
The purpose of Study 1 was: (a) to provide a comprehensive list of medication classes
prescribed to older adults within one year prior to their fall-related injuries. The purpose
of Study 2 was to evaluate the association between fall-related injuries and most
frequently prescribed medication classes prescribed within 30 days prior to the injuries.
The purpose of Study 3 was to explore association between continuously used and newly
initiated medications and fall-related injury in older adults.
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Chapter 2

2

Medication Prescribed within One Year prior to Fall-Related
Injuries in Ontario Older Adults
2.1 Introduction

Falls are the leading cause of both fatal and non-fatal injury in older adults (Bergen &
Stevens, 2016). Nearly one third of older adults fall every year (Chang et al., 2010;
Tinetti et al., 2006). Minor injuries, such as bruises or lacerations, occur in 30-50% of
falls, while 5-10% of falls lead to serious injuries such as hip fractures or traumatic brain
injury (Cameron et al., 2012; Gillespie et al., 2012; Goldacre et al., 2002; Health Quality
Ontario, 2008; Masud & Morris, 2001; Rubenstein & Josephson, 2002). Fall-related
injuries can also result in adverse consequences such as reduced quality of life (Gill et al.,
2013), higher possibility of admission to long-term care facilities (Gill et al., 2013), and
increased risk of death (Skelton & Todd, 2004).
Numerous fall-related risk factors in older adults have been identified through past
research, specific use of certain medications or combinations of medications in particular
was reported to be associated with both increased falls and fall-related injury in this
population (Ambrose et al., 2013; Huang et al., 2012). For instance, psychotropic
medications and concurrent use of more than four medications have consistently been
found to increase falls risk in older adults (Hartikainen et al., 2007; Leipzig et al., 1999;
Park et al., 2015; Woolcott et al., 2009). With increasing knowledge on the association
between medications and falls or fall-related injuries, certain classes of medications were
reported repeatedly to be associated with falls and it was van der Velde who first
proposed the acronym FRID for fall risk-increasing drugs. FRIDs include
antihypertensive agents, diuretics, antidepressants, analgesics, anti-epileptics, and
sedative/ hypnotics (van der Velde et al., 2007; The Swedish National board of Health
and Welfare, 2010) which increase falls and fall-related injuries within older adult
populations (Bauer et al., 2012; Winter et al., 2016; Zia et al., 2017).
While previous research has commonly investigated the association between specific and
known FRIDs, and fall-related injuries (e.g., benzodiazepines (Davies et al., 2018;
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Donnelly et al., 2017); anti-hypertensive medications (Verma et al., 2018, de Vries et al.,
2018); antidepressants (Kurdyak et al., 2007, Axmon et al., 2018), limited evidence
currently exists regarding medication classes of other than FRIDs that were prescribed to
older adults prior to a fall-related injury. Providing a more comprehensive picture of
medication classes prescribed to older adults before the occurrence of a fall-related injury
is necessary to expand our knowledge on medications that may induce any fall-related
injury. Therefore, the purpose of this study was: (1) to describe medication classes and
numbers of medication classes prescribed to older adults within one year prior to the fallrelated injury; and (2) to describe medication classes prescribed to older adults within one
year prior to fall-related fractures and fall-related brain injury, as these two types of
injury are of high prevalence and can cause serious consequences (Court-Brown et al.,
2017; Peterson & Kegler, 2020; Teo et al., 2018)

2.2
2.2.1

Methods
Study Design and Setting

We conducted a population-based, descriptive study of medication classes prescribed to
older adults (>65 years of age) who experienced at least one fall-related injury between
January 1, 2010 and December 31, 2014, using Ontario healthcare administrative data
held by the provincial data steward IC/ES. The extraction of eligible participants in this
study was conducted by IC/ES analysts, based on a carefully prepared data creation plan
(DCP, Appendix B). Ontario is the largest province in Canada, with a population of 14.7
million and 2.6 million older adults over the age of 65 (Statistics Canada, 2020), all of
whom have access to universal healthcare services. IC/ES is an independent, non-profit
research institute whose legal status under Ontario’s health information privacy law
allows it to collect and analyze health care and demographic data. IC/ES is a prescribed
entity under the section 45 of Ontario’s Personal Health Information Protection Act.
Section 45 authorizes IC/ES to collect personal health information, without consent, for
the purpose of analysis or compiling statistical information with respect to the
management of, evaluation or monitoring of, the allocation of resources to or planning
for all or part of the health system. Projects conducted under section 45, by definition, do
not require review by a Research Ethics Board. This project was conducted under section
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45, and was approved by IC/ES’ Privacy and Legal Office. However, ethics approval for
this series of studies was required in Western University, and it was obtained from the
Research Ethics Board at Western University, London, Ontario, Canada (HSREB
#109335, detailed information was provided in Appendix C).

2.2.2

Population

Older adults aged 66 years and older, who experienced a fall-related injury over the study
period (January 1, 2010 to December 31, 2014), and resided in Ontario, were included in
this study. A fall-related injury was defined by combining the ICD-10-CA codes
(Canadian Institute of Health Information [CIHI], 2018a; WHO, 2019a) for falls (W00W19) with codes for injury (S00-S99, T00-T14) (Appendix D). To be included, each
person’s diagnosis necessitated containing at least one W code for falls and at least one S
or T code for injuries. The Emergency Department visit date for a fall-related injury was
defined as the index date. Fall-related injuries of interest in this study were: (1) any fallrelated injury, (2) fall-related fracture; and (3) fall-related traumatic brain injury. Fallrelated fracture was identified through presence of at least one specific fracture S code
(S02, S12, S22, S32, S42, S52, S62, S72, S82, S92, T08, T10, T12, T142) and one W
code (W00-W19). Fall-related traumatic brain injury was identified by presence of at
least one specific concussion and brain injury code (S06, S099) and one W code (W00W19).

2.2.3

Data Sources

We used records arising from several databases held by IC/ES, including: (1) the Ontario
Drug Benefit (ODB) database, which provides prescription drug coverage data for
residents over the age of 65, including individuals in long-term care homes (Government
of Ontario, 2019); (2) the Discharge Abstract Database (DAD), which records
information on all hospital admissions and discharge diagnosis; (3) the National
Ambulatory Care Reporting System (NACRS), which captures information on visits to
emergency departments and community-based ambulatory care facilities; and (4) the
Ontario Registered Persons Database (RPDB), which contains demographic information
for Ontario residents. These datasets were linked using a unique encoded identifier,
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which ensured the confidentiality of personal and health information. We assessed older
adult comorbidities using the various IC/ES-derived data sets, applying validated case
definitions, including diabetes, chronic obstructive pulmonary diseases, asthma,
hypertension, and dementia. Sociodemographic data (i.e., age, sex, and income quintile)
was extracted from the RPDB, primary diagnosis data arose from both NACRS and
DAD, and medication prescriptions were drawn from ODB.

2.2.4

Medication Information

Medication information extracted from the ODB database used the Drug Identification
Number (DIN) assigned by Health Canada (Health Canada, 2018). Each DIN uniquely
identifies the manufacturer, trade name, active ingredients, strength of active ingredients,
pharmaceutical form and route of administration (Health Canada, 2018). For better
understanding and comparability with the results of other studies, DIN codes were
converted and categorized into Anatomical Therapeutic Chemical (ATC) level 5 codes
(see Appendix E). The ATC classification system was devised by the World Health
Organization (WHO) to categorize medications based on the system or organ upon which
they act, as well as their therapeutic and chemical features (WHO, 2019b). In the ATC
classification system, each medication is classified in a hierarchy with 5 levels.
Medication use information was reported on the 4 th level of ATC codes in this study.
ATC 4th level is the level used to count number of different medications as it is the level
which aggregates medications just above their descriptive chemical substance (Krause,
2008).

2.2.5

Outcomes

The primary outcome of this study were medication classes prescribed to older adults
within one year prior to any fall-related injury, fall-related fractures and fall-related
traumatic brain injuries. We quantified any fall-related injury and presented pattens in
medication classes prescribed within the year prior to injury. We also explored
medication prescription patterns within one year prior to both fall-related fractures and
fall-related brain injuries. Finally, the number of ATC 4th level medication classes
prescribed to each older adult within a year was calculated and summarized into four
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categories: 0-4 medication classes, 5-9 medication classes, 10-14 medication classes and
15 or more medication classes (CIHI, 2018a).

2.2.6

Statistical Analysis

Descriptive analysis summarized the cohort baseline characteristics, such as age, sex, age
group, and income quintile. Income quintile is a measure of socioeconomic status that
divides the population living in the same dissemination area into 5 income groups (1
represents the lowest income; 5 represents the highest income) with approximately 20%
of the population in each group (CIHI, 2016). The dissemination area was determined
from the older adults’ residential postal code and statistics Canada Census data (Wilkins,
2010). Comorbidities (i.e., diabetes, chronic obstructive pulmonary diseases, asthma,
hypertension and dementia) were also analyzed using descriptive statistics. The fallrelated injury (any injury type) was reported for each year and as a five-year total (20102014).
The percentage of people prescribed each ATC 4 th level medication class was calculated
by dividing the number of people who were prescribed a certain class within a year prior
to a fall-related injury (numerator) by the total number of older adults who experienced a
fall-related injury (denominator). The formulas are listed below. FRI-OA stands for older
adults who had a fall-related injury.
Percentage of older adults who were prescribed certain medication class prior to a fallrelated injury=

Number of FRI-OAs prescribed certain medication class
Total numbers of FRI-OAs

Percentage of female/male FRI-OAs prescribed Certain Medication Class
=

Number of Female/Male prescribed certain medication class
Number of Female/Male FRI-OAs

Percentage of different Age Group (66-74, 75-84, 85+) FRI-OA prescribed certain
medication class =

Number of Age Group FRI-OA prescribed certain medication class
Number of different Age Group FRI-OAs
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The top 20 medication classes with the highest number of users were summarized as the
percentage of female and male users, and percentage of different age-group users (i.e.,
66-74, 75-84, 85+). The same analysis was repeated for subgroups of older adults who
experienced fall-related fractures and fall-related TBIs. The difference between
percentages of female and male older adults prescribed certain medication classes was
determined by Wilcoxon rank-sum test and the comparison among different age groups
was determined by Kruskal-Wallis test. The numbers of different ATC 4 th level
medication classes prescribed to older adults within one year prior to the fall-related
injuries were counted for each older adult and were categorized into 4 different groups: 04, 5-9, 10-14 and 15 or more medication classes (CIHI, 2018b). All analyses were
conducted with SAS 9.4 (SAS Institute, 2013). All the SAS codes for extracting and
analyzing data were provided in Supplementary Content of this thesis.

2.3

Results

A total of 288,251 older adults experienced any fall-related injury from 2010 to 2014.
Fall-related fractures made up 40.0% of all fall-related injuries, superficial injuries were
23.2%, open wound were 16.3%, traumatic brain injury were 12.1%, sprains and strains
were 5.0%, other injuries were 3.5%. The mean age was 78.3±7.8 years old and 63.2%
of the older adults were female. Over three quarters (76.9%) were diagnosed with
hypertension, 30.5% with diabetes, 26.9% with COPD, 15.8% with dementia and 15.0%
with asthma (Table 2.1) For number of medications prescribed, 3.5% of the study
population were not prescribed any medication classes within one year before the injury,
while 18.9% were prescribed 1-4 different medication classes, 36.4% were prescribed 5-9
different medication classes, 26.0% were prescribed 10-14 different medication classes
and 15.2% were prescribed more than 15 different medication classes. Frequency
distribution of different numbers of medication classes prescribed to older adults prior to
fall-related injuries was presented in Figure 2.1.
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Table 2.1 Characteristics of Older Adults who Experienced Fall-Related Injuries in 2010-2014
2010

2011

2012

2013

2014

2010-2014

78.7±7.6

78.5±7.7

78.5±7.8

78.1±7.9

77.8±8.0

78.3±7.8

79

79

79

78

78

78

56,203

56,230

55,945

58,950

60,923

288,251

Age 66-74 (n, %)

18,673 (33.2)

19,296 (34.3)

19,842 (34.8)

22,160 (37.6)

23,813 (39.1)

103,424 (35.9)

Age 75-84 (n, %)

22,429 (39.9)

22,014 (39.2)

21,551 (38.5)

21,644 (36.7)

21,752 (35.7)

109,400 (38.0)

Age 85+ (n, %)

15,091 (26.9)

14,920 (26.5)

14,912 (26.7)

15,146 (25.7)

15,358 (25.2)

75,427 (26.2)

Sex Female (n, %)

36,562 (65.1)

35,976 (64.0)

35,315 (63.4)

36,492 (61.9)

37,656 (61.8)

182,136 (63.2)

1(lowest)

11,687 (20.88)

11,325 (20.22)

11,169 (20.04)

11,668 (19.87)

13,868 (22.80)

59,717 (20.79)

2

11,525 (20.59)

11,455 (20.46)

11,521 (20.68)

11,953 (20.35)

13,486 (22.17)

59,940 (20.87)

3

11,134 (19.89)

10,922 (19.50)

10,921 (19.60)

11,480 (19.55)

11,816 (19.43)

56,273 (19.59)

4

10,887 (19.45)

11,146 (19.90)

11,208 (20.11)

11,920 (20.30)

10,581 (17.40)

55,742 (19.41)

5

10,737 (19.18)

11,151 (19.91)

10,902 (19.57)

11,712 (19.94)

11,069 (18.20)

55,571 (19.35)

Diabetes (n, %)

16,639 (29.6)

16,926 (30.1)

17,036 (30.5)

18,200 (30.9)

19,161 (31.5)

87,962 (30.5)

COPD (n, %)

15,388 (27.4)

15,207 (27.0)

15,223 (27.2)

15,781 (26.8)

15,963 (26.2)

77,572 (26.9)

Asthma (n, %)

8379 (14.9)

8,374 (14.9)

8,283 (14.8)

8,951 (15.2)

9,192 (15.1)

43,179 (15.0)

Hypertension (n, %)

43,325 (77.1)

43,332 (77.1)

43,197 (77.2)

45,113 (76.5)

46,556 (76.4)

221,523 (76.9)

Dementia (n, %)

9,329 (16.6)

9,175 (16.3)

8.934 (16.0)

9,130 (15.5)

9,007 (14.8)

45,575 (15.8)

Age (Mean±SD)
Age Median
Total Number

Income Quintile

Comorbidities
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Figure 2.1 Frequency Distribution of Different Numbers of Medication Classes Prescribed to Older Adults Prior to Fall-related
Injuries
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Complete medication classes prescribed are provided in Appendix F, Table A1. The top
10 drug classes prescribed within a year before any fall-related injury included HMGCoA reductase inhibitors (C10AA), proton pump inhibitors (PPIs, A02BC), angiotensin
converting enzyme inhibitors (ACEIs, C09AA), beta-blocking agents (C07AB), natural
opium alkaloids (N02AA), dihydropyridine derivatives (C08CA), biphosphonates
(M05BA), thyroid hormones (H03AA), glucocorticoids for systematic use (H02AB) and
benzodiazepine derivatives (N05BA).
HMG-CoA reductase inhibitors, commonly known as statins and used to treat high
cholesterol, were the most commonly prescribed medication class, used by nearly half
(48.5%) of the study population. They were also the most frequently prescribed
medication class in analyses stratified by sex and age sub-groups (Table 2.2 and Figure
2.2). More than half (54.8%) of males were using statins before they experienced an all
cause fall-related injury. In the 75-84 age group, 53.4% used statins and the percentage
dropped to 42.8% in the group of 85 years and older adults.
Proton pump inhibitors (PPIs) were the second most commonly prescribed drug class,
with 34.3% of all older adults. PPIs are usually used to treat gastroesophageal reflux and
peptic ulcer diseases. For age groups 75-84 and 85 years and older, a slightly greater
percentage of PPI use was found (36.2% and 36.5% respectively), while the age group
66-74 years old had somewhat lower prevalence (30.6%).
Four drug classes for the management of hypertension were noted among the top 10 drug
classes. ACEIs were prescribed to 33.9% of male and 26.1% females. A higher
percentage of males were also prescribed beta-blocking agents (Males: 27.8% vs.
Females: 24.8%). However, agents acting on the renin-angiotensin system (RAS) and
thiazides were prescribed in higher percentage to females than males (Table 2.2). The
prescription of agents for treatment of high blood pressure increased with age. The
percentage of 85 years and older age group prescribed ACEIs (C09AA), beta-blocking
agents (C07AB), and dihydropyridine derivatives (C08CA) were the highest among the
three age groups, while the 66-74 age group had of lowest prescription frequency (Figure
2.2).
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Table 2.2 Top 20 Medication Classes Prescribed to Older Adults Prior to a Fall-related Injury, Percentage of Users, 2010-2014
ATC
code

Drug Class

Common Use

C10AA
A02BC
C09AA
C07AB
N02AA
C08CA
M05BA
H03AA

HMG CoA reductase inhibitors
Proton pump inhibitors
ACE inhibitors, plain
Beta blocking agents, selective
Natural opium alkaloids
Dihydropyridine derivatives
Biphosphonates
Thyroid hormones

H02AB

Glucocorticoids

N05BA
C03CA
C09CA
C03AA
J01MA
N06AB
A10BA
J01CA
R03CC
A06AA
N06AX

Benzodiazepine derivatives
Sulfonamides, plain
Agents acting on the renin-angiotensin system
Thiazides, plain
Fluoroquinolones
Selective serotonin reuptake inhibitors
Biguanides
Penicillins with extended spectrum
Selective beta-2-adrenoreceptor agonists
Softeners, emollients
Other antidepressant (TCAs)

High cholesterol
Gastroesophageal reflux, peptic ulcer disease
High blood pressure
High blood pressure, heart failure
Management of moderate to severe pain
High blood pressure, heart failure, angina
Prevent bone density loss, treat osteoporosis
Hypothyroidism
Autoimmune and inflammatory disorders,
cancer, asthma, COPD
Agitation, anxiety, insomnia, seizures
High blood pressure, heart failure
High blood pressure, heart or kidney disease
High blood pressure, heart or kidney disease
Respiratory and urinary tract infections
Depression
Type 2 diabetes
Bacterial infection
COPD, asthma
constipation
Depression

Percentage of Use
Total
Female
(%)
(%)
48.5
44.7
34.3
35.8
29.0
26.1
25.9
24.8
25.0
25.0
23.7
24.8
20.4
28.2
18.3
23.1

Male
(%)
54.8
31.7
33.9
27.8
25.0
21.8
7.1
10.0

p
value
<.01
<.01
<.01
<.01
0.72
<.01
<.01
<.01

17.0

16.6

17.7

<.01

16.6
16.5
16.3
15.2
15.2
14.7
14.3
13.6
13.1
12.9
12.5

19.0
16.0
17.7
17.0
15.2
16.4
12.9
13.6
13.3
12.8
13.5

12.4
17.5
13.8
12.1
15.1
11.9
16.8
13.7
12.8
13.1
10.7

<.01
<.01
<.01
<.01
0.56
<.01
<.01
0.58
<.01
0.04
<.01
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Figure 2.2 Top 10 Medications Prescribed to Older Adults of Different Age Group Before They Experienced Fall-Related Injuries.
Note C10AA, HMG CoA reductase inhibitors; A02BC, proton pump inhibitors; C09AA, ACEIs; C07AB, beta blocking agents;
N02AA, Natural opium alkaloids; C08CA, dihydropyridine derivatives; M05BA, biphosphonates; H03AA, thyroid hormones;
H02AB, glucocorticoids for systematic use; N05BA, benzodiazepine derivatives
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Biphosphonates and thyroid hormones were prescribed to 28.3% and 23.1% of females,
but only to 7.1% and 10.0% males. These two medication classes emerged as the most
gender specific among the older adults who experienced any fall-related injury. The
percentage of older adults prescribed these two drug classes also increased with age with
the age group 85 years and older having the highest percentage (Figure 2.2).
The central nervous system agents, notably natural opium alkaloids, were prescribed to a
quarter of female and male older adults. The highest percentage of opioids prescription
was noted for the age group 75-84 years. Older adults 85 years and older were prescribed
less opioids than the other two age groups. Benzodiazepine derivatives were prescribed to
19.0% females and 12.4% males, with an increase with age to 18.5% in the group of
older adults who were 85 years and older. For antidepressants, such as selective serotonin
reuptake inhibitors (SSRIs) and other antidepressants (mostly tricyclic antidepressants
[TCAs]), there was a higher percentage of female users than male users, namely 16.4%
female, 11.9% male for SSRIs and 13.5% female, 10.7% male for TCAs (Table 2.2).
Fall-related fractures were diagnosed in 115,230 older adults (40.0% of all older adults
with any fall-related injury). More women (70.7%) than men (29.3%) experienced fallrelated factures. For 85 years and older age group, the number of females (22,231) was
almost three times as many as males (7,742). Statins and PPIs were still the top two most
commonly prescribed medication classes. A higher percentage of males were prescribed
statins, ACEIs, and BBs than females, while a higher percentage of females were
prescribed biphosphonates, dihydropyridine derivatives and thyroid hormones. As for age
differences, adults 85 years and older had the highest percentage of prescribed ACEIs,
BBs, biphosphonates, dihydropyridine derivatives, thyroid hormones, benzodiazepine
derivatives, sulfonamides, SSRIs, fluoroquinolones, emollients and other antidepressants
(Table 2.3).
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Table 2.3 Top 20 Medication Classes Prescribed to Older Adults with Fall-Related Fracture, Usage Rate by Sex and Age Group
ATC
Codes

Drug Class

C10AA
HMG CoA reductase inhibitors
A02BC
Proton pump inhibitors
C09AA
ACE inhibitors, plain
N02AA Natural opium alkaloids
C07AB
Beta blocking agents, selective
M05BA Biphosphonates
C08CA
Dihydropyridine derivatives
H03AA Thyroid hormones
N05BA
Benzodiazepine derivatives
H02AB
Glucocorticoids
C09CA
Agents acting on the renin-angiotensin system
C03CA
Sulfonamides, plain
C03AA
Thiazides, plain
N06AB
Selective serotonin reuptake inhibitors
J01MA
Fluoroquinolones
J01CA
Penicillins with extended spectrum
A10BA
Biguanides
R03CC
Selective beta-2-adrenoreceptor agonists
A06AA Softeners, emollients
N06AX Other antidepressants
Note a: Wilcoxon rank-sum test; b: Kruskal-Wallis test.

Total
(%)
45.4
33.1
27.6
24.5
24.5
23.6
23.6
18.6
16.6
16.1
15.7
15.5
14.7
14.6
14.3
13.0
12.7
12.4
12.2
12.1

Female
(%)
42.5
33.9
25.5
24.2
23.7
30.0
24.3
22.3
18.5
15.5
16.7
14.9
16.1
15.7
14.2
13.0
11.7
12.3
11.9
12.8

Sex
Male
(%)
52.4
31.0
32.8
25.2
26.2
8.1
21.8
9.7
12.1
17.4
13.3
16.9
11.3
11.9
14.6
13.1
15.3
12.4
13.0
10.3

pvaluea
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
0.14
0.51
<.01
0.62
<.01
<.01

66-74
(%)
44.6
29.2
23.1
23.7
18.4
18.9
17.7
15.1
13.9
15.3
14.1
8.3
12.8
13.0
11.6
13.7
14.1
12.6
7.8
10.9

Age group
75-84
85+
(%)
(%)
50.4
39.6
35.1
35.4
29.5
31.0
26.0
23.5
26.8
29.3
26.1
26.5
25.2
29.2
18.9
22.7
17.8
18.7
17.0
15.8
17.0
16.0
15.3
25.2
15.7
15.7
14.9
16.4
14.8
17.3
13.3
11.7
14.0
9.2
12.9
11.4
13.3
16.5
12.1
13.5

pvalueb
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
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Table 2.4 Top 20 Medication Classes Prescribed to Older Adults with Fall-Related Traumatic Brain Injury, by Sex and Age Group
ATC
Codes

Drug Class

C10AA
HMG CoA reductase inhibitors
A02BC
Proton pump inhibitors
C09AA
ACE inhibitors, plain
C07AB
Beta blocking agents, selective
C08CA
Dihydropyridine derivatives
N02AA Natural opium alkaloids
M05BA Biphosphonates
H03AA Thyroid hormones
C03CA
Sulfonamides, plain
C09CA
Agents acting on the renin-angiotensin system
H02AB
Glucocorticoids
N05BA
Benzodiazepine derivatives
A10BA
Biguanides
N06AB
Selective serotonin reuptake inhibitors
J01MA
Fluoroquinolones
C03AA
Thiazides, plain
J01CA
Penicillins with extended spectrum
A06AA Softeners, emollients
N06AX Other antidepressants
R03CC
Selective beta-2-adrenoreceptor agonists
Note a: Wilcoxon rank-sum test; b: Kruskal-Wallis test

Total
(%)
52.0
35.5
30.3
28.7
25.1
24.9
19.4
19.1
18.1
17.4
17.3
17.2
16.6
16.5
16.1
15.3
14.4
14.4
13.4
12.8

Female
(%)
48.2
37.5
27.3
27.7
26.5
25.4
28.1
24.8
17.5
19.3
17.2
20.0
15.2
18.6
16.2
17.6
14.7
14.2
14.8
13.3

Sex
Male
(%)
57.4
32.5
34.6
30.2
23.1
24.1
7.0
11.0
19.0
14.8
17.5
13.2
18.6
13.6
16.0
12.1
14.0
14.6
11.5
12.0

pvaluea
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
0.34
<.01
<.01
<.01
0.64
<.01
0.06
0.30
<.01
<.01

66-74
(%)
49.5
31.8
26.1
22.1
19.3
25.0
13.9
15.7
10.3
15.8
16.1
15.7
18.2
15.2
13.0
13.4
15.5
10.1
13.1
13.0

Age group
75-84
85+
(%)
(%)
57.3
47.3
37.3
36.9
31.9
32.7
30.8
33.2
26.9
29.2
25.7
23.5
20.9
23.3
19.0
23.1
17.5
27.6
19.0
17.0
18.3
17.4
17.8
18.0
18.1
12.6
16.9
17.4
16.5
18.9
16.7
15.5
14.2
13.7
15.2
18.1
13.0
14.4
12.9
12.2

pvalueb
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
<.01
0.14
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Fall-related traumatic brain injury was observed in 34,810 older adults (12.1% of all
older adults with any fall-related injury), 20,246 occurred in females (58.7%) and 14,364
in males (41.3%). A third (31.7%) of older adults who experienced fall-related traumatic
brain injury were in the 66-74 age group; with 39.9% and 28.4% in the 75-84 and 85+
years old age groups, respectively. Statins and PPIs were the top two most common
classes of medications. A higher percentage of males diagnosed with fall-related
traumatic brain injury were prescribed statins and ACEIs than females, while higher
percentage of females were prescribed biphosphonates and thyroid hormones. As for age
groups, adults 85 years and older had the highest prescriptions of ACEIs, BBs,
dihydropyridine derivatives, biphosphonates, thyroid hormones, sulfonamides,
benzodiazepine derivatives, SSRIs, fluoroquinolones, emollients and other
antidepressants (Table 2.4).

2.4

Discussion

Using health care administrative data, this population study has described the medication
classes prescribed to older adults in one year prior to a fall-related injury and two specific
fall-injury types, namely fracture and traumatic brain injury. The results showed that
among older adults sustaining any fall-related injury, 48.5% were prescribed statins,
34.3% PPIs, 25.0% opioids, and16.6% anxiolytics. Similar patterns of medication
prescription were also found for fall-related fractures and traumatic brain injury. Notably,
36.4% of older adults were prescribed 5-9 different medication classes and 41.2% were
prescribed 10 or more medication classes within one year prior to fall-related injuries.
The findings of this study indicated that medications prescribed to older adults who had
any fall-related injury were similar, but not the same to medications prescribed to the
general population of older adults in Ontario (CIHI, 2018b). CIHI reported that, in the
whole year of 2016, there were 51.7% and 17.3% of Ontario general population of older
adults (OGP-OAs) who were prescribed statins and agents acting on RAS (CIHI, 2018b),
while in our study, 48.5% and 16.3% of older adults who had fall related injury (FRIOAs) were prescribed statins and agents acting on RAS within the year before the injury.
However, compared to prescription in OGP-OAs, higher percentage of FRI-OAs were
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prescribed with ACEIs, BBs, opioids, biphosphonates, benzodiazepine derivatives,
thiazides, and SSRI. For example, CIHI reported there were 15.4% of OGP-OAs
prescribed opioids, while in our study, 25.0% of FRI-OAs were prescribed opioids the
year before their fall-related injury. The percentage of being prescribed SSRI in FRI-OAs
and OGP-OAs were 14.6% and 10.5% respectively, biphosphonates were 20.4% and
9.4% respectively, benzodiazepine derivatives were 15.2% and 10.8% respectively.
The above comparison confirmed that all medication classes (except biphosphonates)
with a higher percentage of prescription in older adults who had any fall-related injury
were recognized as FRIDs. These classes of medications have been repeatedly identified
to be related to falls and fall-related injury (Lee & Holbrook, 2017; Machado-Duque et
al., 2018; Richardson et al., 2015; Seppala, Wermelink, et al., 2018). Most studies
currently identify anti-hypertensive agents, antidepressants, antiepileptics, analgesics,
sedatives and hypnotics, anti-Parkinsonian drugs, antipsychotics, and anxiolytics as
FRIDs. In this aspect, our findings support previous studies on FRIDs and their
association with falls and fall-related injury.
In this study, however, a number of other medication classes such as statins (48.5%),
PPIs (34.3%), biphosphonates (20.4%), thyroid hormones (18.3%), glucocorticoids
(17.0%), and fluoroquinolones (15.2%) were prescribed to a high percentage of older
adults. Unfortunately, research regarding the association between these medication
classes and fall-related injuries has not been well established (de Vries et al., 2018;
Seppala, van de Glind, et al., 2018). The link between these commonly prescribed
medication classes and fall-related injury in older adults needs to be further explored.
Of all fall-related injury types, fractures are the most common (PHAC, 2014). Findings in
this study showed that medications prescribed prior to fall-related fractures were similar
to medication prescribed prior to any fall-related injury. Hip fractures were extensively
used in research as fall-related outcome because they were almost always caused by falls
and were hospitalized, minimizing the number of missing cases (Hayes et al., 1996;
Manchado-Duque et al., 2018, Payne et al., 2013, Thaler et al., 2016). A number of
studies reported different percentages of older adults using certain medications prior to
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hip fractures because their lookback windows were dissimilar. For example, Wang et al.
(2000) reported 2.2% of older adults were prescribed statins within 180 days prior to hip
fractures, while Rejnmark et al. (2004) reported that 66% of Danish older adults used
statins within five years prior to hip fracture. A Swedish population-based study reported
53% of older adults who were 75 years and older used diuretics, 43% BBs, 18% CCBs,
30% agents acting on RAS, 33% opioids, 25% anxiolytics, 37% hypnotics and sedatives
and 29% antidepressants within one year prior to a hip fracture (Thorell et al., 2014).
Percentage of older adults prescribed antihypertensive medications and psychotropic
medications in Thorell’s study (2014) were much higher than ours. Possible explanation
could be that their participants were older and their only outcome was hip fractures.
Fall-related TBIs in older adults are gaining increasing recognition in recent studies
(Kannus et al., 2007; Hartholt et al., 2011). Currently only anticoagulants and antiplatelet
agents were reported to be associated with TBIs due to an increased risk of intracranial
bleeding (Boltz et al., 2015; Qiu et al., 2019). However, our finding indicated that higher
percentage of statins, PPIs, ACEIs, BBs, sulfonamides, SSRIs and biguanides were
prescribed prior to fall-related TBIs than fall-related fractures, which offers a good
starting point for further exploration of the association between these medications and
fall-related TBIs.
Medications can be seen as a surrogate for a person’s health status and the number of
medications a valid proxy for multi-comorbidities (Schneeweiss et al., 2001). Using
multiple medications concurrently is common in older adults with multi-comorbidities
and is associated with adverse outcomes such as mortality, falls, injuries, adverse drug
reactions, and prolonged length of stay in hospital (Caughey et al., 2010; Correa-Pérez et
al., 2017; Milton et al., 2008). The risk of having adverse consequences and experiencing
harm increased with each additional medication because of complicated drug-drug and
drug-disease interactions (Maher et al., 2014). Our study showed that 77.6% of older
adults who had any fall-related injury were prescribed five or more different classes of
medication within one year before the injury and 41.2% were prescribed ten or more
different classes of medication. CIHI reported that 65.7% general population of older
adults in Canada were prescribed five or more medication classes and 26.5% were
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prescribed ten or more medication classes in the year of 2016 (CIHI, 2018b). Compared
with the general population of older adults, a higher percentage of older adults who
experienced fall-related injuries were prescribed multiple medication classes before the
injury. Untangling multiple medications prescribed to older adults by enhancing
communication between patients and healthcare providers, improving cooperation of
pharmacists, family doctors, and specialists in prescribing practices will be important in
future research.

2.4.1

Strengths and Limitations

The strengths of this study are the large number of observations and provincial
representativeness. This study included data for over a quarter million older adults and
provided detailed information on demographics, comorbidities and strictly defined fallrelated injury using ICD-10-CA codes. All the data were obtained from IC/ES databases
which were reported to have excellent data completeness (Levy et al., 2003) and high
quality as in previous studies (Aiken et al., 2016; Liu et al., 2018; Macri et al., 2017).
Several limitations are associated with this study. First is the inherent limitation of
administrative data that may lead to underreporting of some diagnoses (Sarrazin &
Rosenthal, 2012), which might have been omitted during the coding process. Second,
only dispensed drugs were recorded in the ODB database and the information collected
through the ODB database could be an underestimation of prescriptions. Additionally,
prescription (and even dispensing) cannot be equated with actual use, therefore the
registry data could be an overestimation of drug use in our population of older adults.
This study laid the foundation for the consecutive studies in this program of research.
With the knowledge of medication classes being prescribed to older adults prior to a fallrelated injury, a comparison of medication classes prescription patterns between older
adults who had a fall-related injury and older adults without a fall-related injury is now
possible, which is essential in the upcoming case-control studies examining the
association between medication and fall-related injuries. Future research could also
include examine the association between medication prescribed to older adults and
different types of fall-related injuries and evaluate the effectiveness of interventions
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aimed at improving the appropriateness of prescribing in older adults to reduce the
occurrence of fall-related injury.

2.5

Conclusion

This study described the medications classes and numbers of medication classes
prescribed to older adults prior to a fall-related injury. Gender difference in medication
prescribed was noted, specifically more females were prescribed antidepressants and
anxiolytics. A higher percentage of people 85 years and older were prescribed
antihypertensive agents, anxiolytics and antidepressants. There were 77.6% of older
adults who were prescribed five or more different medication classes prior to any fallrelated injury. Well-designed cohort studies are needed to determine the association
between medication classes and different types of fall-related injuries.
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Chapter 3

3

Association between Fall-related Injury and Medication
Prescribed to Older Adults within One Month Prior to the Injury

3.1

Introduction

Roughly 30% of older adults aged 65 years or older fall every year (Chang et al., 2010;
Tinetti et al., 2006). Falls are the leading cause of non-fatal injuries and death among
older adults in many countries and regions (Bergen et al., 2016; Ellingsen et al., 2018;
National Council of Aging, 2018; Public Health Agency of Canada, 2014). Not all falls
result in injuries, some minor injuries that may or may not require medical treatment or
consultation, occur in 30-50% of falls, while 5-10% of falls lead to serious injuries such
as fractures, dislocation of joints, or brain injury (Cameron et al., 2012; Gillespie et al.,
2012; Goldacre et al., 2002; Health Quality Ontario, 2008). Although there is no
consensus on the definition of fall-related injury, most studies refer to it as “an injury
requiring emergency or inpatient treatment” (Schwenk et al., 2012). Fall-related injuries
can result in adverse consequences both to individuals and to the public health care
system (Burns et al., 2016; Gill et al., 2013, Scott et al., 2010). Disability resulting from
falls increased by 54% in United States between 1990 and 2010 (Murray et al., 2013). In
2010, injurious falls in older adults in Canada resulted in over $3.3 billion in direct costs
to the public health care system (Parachute, 2015). The total cost of fall-related injury in
U.S was $50 billion in 2015 (National Council of Aging, 2018). Subsequently, it has
become increasingly recognized that fall-related injury is a growing public health
concern, especially with an increasing aging demographic (He et al., 2016).
The risk factors for fall-related injuries in older adults are multifactorial. History of
previous falls, age, mobility and balance problems, and certain medication classes were
reported to be associated with fall-related injuries (Gillespie et al., 2012; Mccoy, et al.,
2017; Nilsson et al., 2016). Many studies demonstrated that use of certain medications
and concurrent use of more than four medications enhanced the risk of falls and fallrelated injury in older adults (Ambrose et al., 2013; Huang, et al., 2012; Pan et al., 2014;
Hart et al., 2019). A recent systematic review reported that loop diuretics enhanced the
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risk of falls by 36%, and antipsychotics, analgesics such as opioids, antidepressants and
benzodiazepines were associated with increasing the risk for injurious falls by 60-80% in
older adults (Seppala, Wermelink, et al., 2018). Polypharmacy was also identified as
being associated with an increased risk of fall-related injuries and fractures (Iihara et al.,
2016; Pan et al., 2014).
However, previous studies have focused mainly on fall-risk increasing drugs (FRIDs)
such as anti-hypertensives and drugs acting on the nervous system. Currently lacking in
the research literature are studies examining the association between medications
currently not listed on the established FRID list (the Swedish National Board on Health
and Welfare, 2010) and fall-related injury in older adults. Furthermore, there is a lack of
robust evidence related to whether exposure to statins, proton pump inhibitors (PPIs),
antiplatelets, glucose-lowering medications, laxatives, and anticholinergic drugs are
associated with fall-related injury (Seppala, van de Glind, et al., 2018). This is important
as these are considered commonly prescribed medications. For example, Canadian
Institute for Health Information ([CIHI], 2018a) reported that these types of medication
have been prescribed to 30-50% of older adults in the province of Ontario, Canada.
Therefore, it is necessary to expand inquiry beyond FRIDs to include more medication
classes and explore their association with fall-related injury. The purpose of this study
was to evaluate the association between fall-related injuries and medication classes
prescribed to older adults within 30 days prior to the injury.

3.2
3.2.1

Methods
Study Design

We conducted a population-based, case-control study using administrative secondary
health care data for Canada’s most populous province of Ontario. Ontario is the largest
province in Canada, with a population of 14.7 million and 2.6 million older adults over
the age of 65 (Statistics Canada, 2020), all of whom have access to universal healthcare
services. The extraction of eligible participants in this study was conducted by IC/ES
analysts, based on a carefully prepared data creation plan (DCP, Appendix B). IC/ES is
an independent, non-profit research institute whose legal status under Ontario’s health
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information privacy law allows it to collect and analyze health care and demographic
data. IC/ES is a prescribed entity under the section 45 of Ontario’s Personal Health
Information Protection Act. Section 45 authorizes IC/ES to collect personal health
information, without consent, for the purpose of analysis or compiling statistical
information with respect to the management of, evaluation or monitoring of, the
allocation of resources to or planning for all or part of the health system. Projects
conducted under section 45, by definition, do not require review by a Research Ethics
Board. This project was conducted under section 45, and was approved by IC/ES’
Privacy and Legal Office. However, ethics approval for this series of studies was required
in Western University, and it was obtained from the Research Ethics Board at Western
University, London, Ontario, Canada (HSREB #109335, detailed information was
provided in Appendix C).

3.2.2

Data Sources

We used records from three databases held by IC/ES: (1) the Ontario Drug Benefit
(ODB) database, which provides prescription drug coverage data for residents over the
age of 65, including individuals in long-term care homes (Government of Ontario, 2019);
(2) the National Ambulatory Care Reporting System (NACRS), which captures
information on visits to emergency departments (EDs) and community-based ambulatory
care facilities; and (3) the Ontario Registered Persons Database (RPDB), which contains
demographic information for Ontario residents. These datasets were linked using unique
encoded identifiers and analyzed at IC/ES, which ensured the confidentiality of personal
and health information.
Diagnoses were extracted from NACRS database and medication prescribed within 30
days was drawn from the ODB database. Age, sex, residence area (i.e., Local Health
Integration Networks [LHINs]), and neighborhood income quintile were extracted from
RPDB dataset. LHINs are the 14 health authorities that are responsible for the regional
public healthcare service in Ontario (LHINs, 2020). Neighborhood income quintile is a
measure of socioeconomic status that divides the population living in same dissemination
area into 5 income groups (1 represents the lowest income; 5 represents the highest
income) with approximately 20% of the population in each group (CIHI, 2016).

66

3.2.3

Selection of Cases and Controls

The cases in this case-control study had to fulfill the following criteria: (a) residing in
Ontario; (b) 66 years and older, (c) visited ED for fall-related injury between January 1,
2010 and December 31, 2014. The ODB program covers the cost of prescription
medications for all Ontarians 65 years and older, therefore those under the age of 66 were
excluded to avoid incomplete medication information in their first year of eligibility.
Patients who visited an ED for fall-related injury were captured by the NACRS database.
The ICD-10-CA codes (CIHI, 2018b; World Health Organization [WHO], 2020) were
used to confirm patients’ diagnosis. Fall-related injury in this study was defined by
combining the ICD-10-CA codes for falls W00-W19, and codes for injury S00-S99 or
T00-T14 (Appendix D). The date when the patient was admitted to the ED due to a fallrelated injury was defined as the index date. For individuals who have had multiple
entries to EDs, only the information of first entry was used. Cases were excluded if they
had experienced an in-hospital fall-related injury, were transferred from another ED, left
the ED without being registered, had a scheduled ED visit or died in ED. Controls were
older adults without a fall-related injury diagnosis extracted from Ontario RPDB, and
matched to cases by the same age, sex, and LHIN, with no fixed ratio. An index date was
assigned randomly to each control within the five-year study period. As the authors had
no access to the database hosted by IC/ES, all of the above operations were completed by
an IC/ES analyst according to a pre-agreed DCP (Appendix B) to generate the matched
dataset, which was then provided to the research team.

3.2.4

Medication Use

Use of a certain medication class within 30 days prior to a fall-related injury was
regarded as one of the risk factors for fall-related injury. Medications prescribed to case
and control groups were extracted from ODB datasets. ODB datasets uses Drug
Identification Numbers (DIN) assigned by Health Canada (Health Canada, 2018) to
identify different medications. Each DIN included information on medication’s
manufacturer, trade name, active ingredients, strength of the active ingredients,
pharmaceutical form, and route of administration (Health Canada, 2018). In order to
better understand and compare findings of this study with the results of other studies,
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DIN codes were converted to Anatomical Therapeutic Chemical (ATC) level 5 codes and
grouped into 4th level codes. In ATC classification system, each medication is classified
in a hierarchy with five levels (WHO, 2019). The 1st level includes fourteen anatomical
main groups. These main groups are divided into 2nd level which is the pharmacological
or therapeutic group. The 3rd and 4th levels are chemical, pharmacological or therapeutic
subgroups and the 5th level is the chemical substance. ATC 4th level is the level used to
count number of different medications because it is the level which aggregates
medications just above their descriptive chemical substance (Krause, 2008).The numbers
of older adults who were prescribed with each ATC 4 th level medication class in both the
case and control groups were calculated and the analysis of the association between each
medication class and fall-related injury was conducted.

3.2.5

Statistical Analysis

The difference between case and control groups characteristics such as age, sex, income
quintile, residence area (LHINs), and the number of medication classes prescribed were
evaluated by Wilcoxon rank sum test, with a significance level of .01. Due to multiple
testing, a conservative Bonferroni adjustment for p-value of each individual test was
applied. If the adjusted p-value >1, we define it as 1.00. Older adults were categorized
into three age groups, aged 66-74, 75-84, and 85+. The number of medication classes
prescribed to each older adult within 30 days of the fall-related injury was calculated and
classified into one of four categories: 0-4, 5-9, 10-14, and 15 or more different
medication classes (CIHI, 2018a). An examination of the extracted data revealed that
there were significant differences between the case and control groups on matched factors
such as age, sex and LHINs, so the matching seemed to be incomplete. To address the
potential for residual confounding, these factors were included in the adjusted
multivariable model. Univariate logistic regression was used to calculate the unadjusted
Odds Ratios (ORs) and 99% confidence intervals (CIs) for medication classes.
Medication classes for topical use (ATC ‘D’ codes) and treatment of cancer (ATC ‘L’
codes) were excluded. Multivariate logistic regression model was conducted for each
medication class, adjusted for sex, age group, residence area (LHINs), neighborhood
income quintile, and number of medication classes prescribed. The corresponding ORs
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were recorded as adjusted ORs (aORs). Attributable risk among the exposed group (older
adults who were prescribed with each medication class) and population attributable risk
were calculated for each medication class. All the analysis was conducted with SAS 9.4
(SAS Institute, 2013).

3.3

Results

This study included 1,005,066 community-dwelling older adults. The case group
included 255,270 older adults who experienced a fall-related injury over the five-year
period. The mean age of the cases was 77.7±7.7 years and 61.1% were female. The
control group included 749,796 older adults, with a mean age of 75.1±7.5 years old and
54.0% female. The case and control groups were similar in income quintile distribution
but were significantly different in LHINs, age group constitution, female percentage, and
number of prescribed medication classes (Table 3.1).
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Table 3.1 Characteristics of Case and Control Group
Case
Control
p
aORsb
a
(n = 255,270)
(n = 749,796) value
(99%CI)
Age Mean±SD
77.7±7.7
75.1±7.5
Age group 66-74 (N, %)
100,027 (39.2) 405,172 (54.0) <.01
Reference
Age group75-84 (N, %)
96,874 (37.9)
235,486 (31.4) <.01
1.57 [1.55, 1.59]
Age group 85+ (N, %)
58,396 (22.9)
109,138 (14.6) <.01
1.85 [1.82, 1.88]
Female (N, %)
157,957 (61.1) 415,513 (54.6) <.01
1.30 [1.29, 1.32]
Local Health Integration Networks, LHINs (N, %)
LHIN 01 Erie St. Claire
13,652 (5.3)
39,302 (5.2)
.23
1.21 [1.16, 1.25]
LHIN 02 South West
21,286 (8.3)
54,948 (7.3)
<.01
1.42 [1.37, 1.47]
LHIN 03 Waterloo Wellington
12,654 (5.0)
37,835 (5.0)
.30
1.21 [1.16, 1.26]
LHIN 04 Hamilton Niagarac
32,006 (12.5)
87,984 (11.7)
<.01
1.28 [1.23, 1.32]
LHIN 05 Central West
10,915 (4.3)
38,676 (5.2)
<.01
Reference
LHIN 06 Mississauga Halton
17,264 (6.8)
56,762 (7.6)
<.01
1.08 [1.05, 1.12]
LHIN 07 Toronto Central
20,608 (8.1)
63,701 (8.5)
<.01
1.12 [1.08, 1.16]
LHIN 08 Central
29,636 (11.6)
95,770 (12.8)
<.01
1.09 [1.05, 1.12]
LHIN 09 Central East
30,768 (12.1)
92,220 (12.3)
<.01
1.19 [1.15, 1.23]
LHIN 10 South East
13,040 (5.1)
34,213 (4.6)
<.01
1.41 [1.36, 1.47]
LHIN 11 Champlain
24,762 (9.7)
72,939 (9.7)
1.00
1.21 [1.17, 1.25]
LHIN 12 North Simcoe Muskoka
9,797 (3.8)
26,681 (3.6)
<.01
1.35 [1.29, 1.41]
LHIN 13 North East
13,621 (5.3)
35,414 (4.7)
<.01
1.38 [1.33, 1.49]
LHIN 14 North West
5,261 (2.1)
13,351 (1.8)
<.01
1.42 [1.33, 1.49]
Neighborhood Income Quintile (N, %)d
1
52,413 (20.5)
150,600 (20.1) <.01
0.94 [0.92, 0.96]
2
53,161 (20.8)
156,131 (20.8) 1.00
0.97 [0.95, 0.99]
3
50,081 (19.6)
146,952 (19.6) 1.00
0.98 [0.96, 1.00]
4
49,793 (19.5)
144,927 (19.3) .26
1.01 [0.99, 1.03]
5 (highest income)
49,822 (19.5)
151,186 (20.2) <.01
Reference
Number of Medication Classes (N, %)
0-4
179,175 (70.2) 635,056 (84.7) <.01
Reference
5-9
55,233 (21.6)
90,111 (12.0)
<.01
1.95 [1.92, 1.98]
10-14
17,194 (6.7)
21,036 (2.8)
<.01
2.50 [2.43, 2.57]
15+
3,667 (1.4)
3,593 (0.5)
<.01
3.23 [3.04, 3.44]
a
Note. Bonferroni-adjusted p value;
b adjusted ORs were obtained by putting age group, sex, LHINs, income quintile and
number of medications into a multivariate regression model.
c LHIN4: Hamilton Niagara Haldimand Brant;
d Neighborhood income quintile is a measure of socioeconomic status that divid es the
population living in same dissemination area into 5 income groups (1 represents the
lowest income; 5 represents the highest income) with approximately 20% of the
population in each group
Characteristics
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One hundred and fifty medication classes entered the univariate and multivariate
regression model. Given the numerous study covariates, only association between fallrelated injury and ATC 4th medication classes with an aOR>1.20 and more than 10,000
older adult users were presented in Table 3.2. Proton pump inhibitors (PPIs, A02BC),
statins (C10AA), pennicillins with extended spectrum (J01CA) and biphosphonates
(M05BA) were associated with increasing the odds of fall-related injury by 20-30%.
Drugs for constipation (A06AA, A06AB), testosterones (G04CB), anticholinesterases
(N06DA), and drugs for asthma (R03CC) were associated with increasing the odds of
fall-related injury by over 50%. Older adults prescribed with non-steroid antiinflammatory drugs (NSAIDs) such as propionic acid derivatives (M01AE), antiepileptics (N03AX) were over two times more likely to experience fall-related injury than
non-users (M01AE: aOR=2.36, 99%CI [2.24-2.49]; N03AX: aOR=2.02, 99%CI [1.922.13]). Using opioids (N02AA) increased the likelihood of having a fall-related injury by
3.5 times (aOR=3.55, 99%CI [3.48-3.62]).
The attributable risk (AR) percentages among exposed group and population attributable
risk (PAR) percentages were shown in Table 3.3. Low PARs indicate that either the risk
of experiencing fall-related injury is low, or that prescription of particular medication is
not prevalent (or both). Avoiding prescribing these medications will have little effect in
preventing fall-related injuries. A high PAR indicates that avoiding prescribing these
medications could be effective in preventing fall-related injuries. For example, 76.87% of
older adults who were prescribed natural opium alkaloids experienced fall-related injuries
and 13.04% of all cases of fall-related injuries could be prevented if no natural opium
alkaloids were prescribed. The findings of Study 1 indicate that avoiding prescriptions of
proton pump inhibitors, emollients, contact laxatives, platelet aggregation inhibitors,
statins, biphosphonates, SSRIs, TCAs, anticholinesterases and selective beta-2adrenoreceptor agonists could have considerable impacts on reducing the fall-related
injuries in older adults.
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Table 3.2 Association between Different Medication Classes and Fall-related Injury in Older Adults
ATC
Crude OR
aOR*
Drug Classes and Indications
Common Indications
codes
(99%CI)
(99%CI)
A02BC Proton pump inhibitors
for gastric ulcer and GERD
1.97 [1.93, 2.00] 1.21 [1.19, 1.24]
A06AA Softeners, emollients
for constipation
2.90 [2.81, 2.99] 1.70 [1.64, 1.75]
A06AB Contact laxatives
for constipation
2.69 [2.59, 2.79] 1.58 [1.52, 1.64]
B01AC Platelet aggregation inhibitors excl. heparin
prevent thrombosis
2.19 [2.12, 2.27] 1.31 [1.27, 1.36]
C10AA HMG CoA reductase inhibitors
lower lipids
1.72 [1.70, 1.75] 1.25 [1.23, 1.27]
C10AZ Other lipid modifying agents
lower lipids
1.75 [1.67, 1.83] 1.32 [1.25, 1.38]
G04BD Drugs for urinary frequency and incontinence for incontinence
2.28 [2.17, 2.40] 1.34 [1.27, 1.41]
G04CA Alpha-adrenoreceptor antagonists
for benign prostatic hyperplasia
1.78 [1.72, 1.84] 1.36 [1.32, 1.41]
G04CB Testosterone-5-alpha reductase inhibitors
for benign prostatic hyperplasia
1.97 [1.88, 2.07] 1.58 [1.50, 1.66]
J01CA Penicillins with extended spectrum
for bacterial infection
1.50 [1.43, 1.57] 1.27 [1.21, 1.34]
M01AB Acetic acid and related substances
anti-inflammation
1.64 [1.56, 1.73] 1.36 [1.29, 1.44]
M01AE Propionic acid derivatives
anti-inflammation
2.68 [2.55, 2.83] 2.36 [2.24, 2.49]
M01AH Coxibs
anti-inflammation
1.91 [1.82, 2.02] 1.40 [1.32, 1.48]
M05BA Biphosphonates
preventing osteoporosis
1.93 [1.89, 1.98] 1.30 [1.27, 1.33]
N02AA Natural opium alkaloids
for moderate to severe pain
4.32 [4.24, 4.41] 3.55 [3.48, 3.62]
N03AX Other antiepileptics
for epilepsy
3.07 [2.92, 3.23] 2.02 [1.92, 2.13]
N05AH Diazepines, oxazepines, thiazepines and oxepines for schizophrenia
2.34 [2.25, 2.44] 1.28 [1.23, 1.34]
N06AA Non-selective monoamine reuptake inhibitors for anxiety, tension and depression
1.91 [1.82, 2.00] 1.25 [1.19, 1.31]
N06AB Selective serotonin reuptake inhibitors
for anxiety, tension and depression
2.98 [2.91, 3.06] 1.84 [1.79, 1.90]
N06AX Other antidepressants
for anxiety, tension and depression
2.59 [2.52, 2.66] 1.54 [1.49, 1.58]
N06DA Anticholinesterases
for Alzheimer's and myasthenia gravis 2.82 [2.74, 2.91] 1.53 [1.48, 1.58]
R03CC Selective beta-2-adrenoreceptor agonists
for asthma/COPD
2.30 [2.22, 2.39] 1.57 [1.51, 1.63]
Note. *OR adjusted for sex, age group, LHINs, income quintiles, and number of medication classes prescribed;
GERD: gastro-esophageal reflux disease. BPH: benign prostatic hyperplasia. COPD: chronic obstructive pulmonary disease
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Table 3.3 Attributable Risk Percentage of Exposed Group and Population Attributable
Risk (PAR) for Each Medication Class
ATC
PAR
Drug name
ARe (99%CI)*
codes
(%)
49.12 [48.22-50.01]
A02BC
Proton pump inhibitors
7.66
65.48 [64.43-66.50]
A06AA
Softeners, emollients
3.86
62.84 [61.45-64.18]
A06AB
Contact laxatives
2.38
54.34 [52.78-55.84]
B01AC
Platelet aggregation inhibitors excl. heparin
2.25
41.92 [41.04-42.79]
C10AA
HMG CoA reductase inhibitors
9.09
42.70 [39.91-45.37]
C10AX
other lipid modifying agents
0.79
56.05 [53.77-58.22]
G04BD
Drugs for urinary frequency and incontinence
1.03
43.75 [41.91-45.54]
G04CA
Alpha-adrenoreceptor antagonists
1.81
49.30 [46.80-51.69]
G04CB
Testosterone-5-alpha reductase inhibitors
0.94
33.23 [29.91-36.40]
J01CA
Penicillins with extended spectrum
0.56
39.09 [35.76-42.24]
M01AB Acetic acid and related substances
0.57
62.73 [60.73-64.62]
M01AE
Propionic acid derivatives
1.17
47.73 [44.90-50.41]
M01AH Coxibs
0.75
48.26 [47.02-49.47]
M05BA Biphosphates
3.94
76.87 [76.40-77.32]
N02AA
Natural opium alkaloids
13.04
67.40 [65.68-69.03]
N03AX
Other antiepileptics
1.38
N05AH
Diazepines, oxazepines, thiazepines and oxepines 57.30 [55.59-58.94]
1.78
47.56 [45.02-49.98]
N06AA
Non-selective monoamine reuptake inhibitors
0.93
66.45
[65.57-67.31]
N06AB
Selective serotonin reuptake inhibitors
5.33
61.31
[60.23-62.35]
N06AX
Other antidepressants
4.14
64.59
[63.45-65.70]
N06DA
Anticholinesterases
3.36
56.51
[54.87-58.09]
R03CC
Selective beta-2-adrenoreceptor agonists
1.97
Note *ARe=Attributable Risk Percentage among exposed group (Exposed refers to older
adults who were prescribed certain medication class)
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3.4

Discussion

This population-based, case control study examined the association between fall-related
injury and medication classes prescribed to older adults within 30 days prior to the injury.
The result of our study provided novel findings on several mediation classes that were
associated with increased odds of fall-related injury in older adults, such as medication
classes used for benign prostatic hyperplasia, bacterial infections and bronchodilators.
Previous studies have reported a positive association between fall-related injury in older
adults and drugs acting on the central nervous system (CNS) such as opioids (N02A)
(Söderberg et al., 2013), antiepileptics (N03) (Resnick et al., 2012; Sylvestre et al., 2012),
anti-Parkinson agents (N04) (Resnick et al., 2012), antipsychotics (N05A) (Byers, et al.,
2008; Resnick et al., 2012), antidepressants (N06A) (Kerse et al., 2008; Sterke et al.,
2012), and anticholinesterases (N06DA) (Richardson et al., 2015; Salahudeen et al.,
2015). Findings from our study were consistent with these studies, but unique to our
study is that all of our assessments on different medication classes came from the same
population, while other studies had various target populations (Kerse et al., 2008;
Resnick et al., 2012; Sylvestre et al., 2012); or were focused on one or two specific
medication classes (Kerse et al., 2008; Söderberg et al., 2013). The explanations why
these medication classes were associated with falls and fall-related injuries focused on
side effects such as confusion, blurred vision, dizziness, sedation, postural hypotension,
and extra-pyramidal effects (Daoust et al., 2018; Hill & Wee, 2012; Joe & Forester, 2010;
Masud et al., 2013; Quach et al., 2013).
Kelly et al. (2003) and Kuschel et al (2015) used population-based, administrative data to
identify a wide range of medication classes that were associated with fall-related injury in
older adults (Kelly et al., 2003; Kuschel et al., 2015). Both studies captured medication
prescription within 30 days prior to the fall-related injury in older adults. Kelly et al.
(2003) used health registry data from Alberta, Canada in 1997/1998 fiscal year. They
found that narcotic pain killers, anti-convulsants (anti-epileptics), and anti-depressants
were independently associated with an increased risk of sustaining injurious falls. The
authors tried to eliminate the influence of comorbidities by using various comorbidities as
confounding factors. However, this is complicated because multiple medication classes
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could be used in the treatment of one comorbidity while one medication class could be
used to treat multiple comorbidities. The real effect of each single medication class on
injurious falls is difficult to fully define. Kuschel and colleagues (2015) reported twenty
most commonly prescribed ATC 3rd medication classes and their association with fallrelated injuries using Swedish public health data. Additional to CNS drugs (N02A,
N02B, N05C and N06A), drugs for peptic ulcer (A02B), constipation drugs (A06A),
antithrombotic agents (B01A), Vitamin B12 (B03B), Calcium (A12A), and NSAIDs
(M01A) were reported to be independently associated with fall injuries. Consistent with
Kuschel et al., our study found a positive association between PPIs (A02BC),
constipation drugs (A06AA, A06AB), anti-thrombotic agents (B01AC, B01AE), and
NSAIDs (M01AB, M01AE, and M01AH) and fall-related injury. What is new in our
findings, is positive association of lipid-lowering agents (statins, C10AA), drugs for
benign prostatic hyperplasia (G04CA and G04CB), pennicillins with extended spectrum
(J01DB), biphosphonates (M05BA), and selective 𝛽-2-adrenoreceptor agonists for
asthma (R03CC) with fall-related injuries in older adults.
A recent systematic review by de Vries et al. (2018) reported that statins had a protective
effect on fall-related injury in older adults. Contrary to this, our study identified that
statins were associated with increased odds of fall-related injuries (aOR= 1.25, 99%CI
[1.23-1.27]). Other studies have described that the side effects of statins, such as
myopathy and muscle weakness, were more prevalent and serious in elderly patients than
younger patients (Horodinschi et al., 2019; Mansi et al., 2013). Muscle disorders
associated with statins contribution to older adults’ physical deconditioning and frailty
(Curfman, 2017) could in part explain increased risk for fall-related injury. According to
the CIHI 2018 report, statins were prescribed to nearly half of Canadian older adults, but
percentage of statins users decreased with age (CIHI, 2018a). Future studies are needed
to explore the impact of statins on fall-related injury in different age groups of older
adults. They will provide clinicians with more confidence in balancing the risk and
benefit in prescribing statins to older adults.
The finding that 𝛼 -adrenoreceptor antagonists (G04CA) and testerones-5 𝛼 reductase
inhibitors (G04CB) might increase the odds of fall-related injury in older adults by 36-
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58% was rather new. The 𝛼-adrenoreceptor antagonists are used for the treatment of
hypertension, so it is plausible that known side effects of 𝛼-adrenoreceptor antagonists,
such as orthostatic hypotension, dizziness, drowsiness and fatigue could lead to fallrelated injuries (Sica, 2005). Testerones-5 𝛼 reductase inhibitors have some
cardiovascular side effects, such as syncope and hypotension that could also lead to falls
and serious fall-related consequences (Lee & Cho, 2018). Welk et al. (2015) did not find
that using 5 𝛼 reductase inhibitors was related to fractures (OR = 0.88, 95% CI [0.701.10]), but they explained that physicians prescribed 5 𝛼 reductase inhibitors only to
older adults that were judged to have low risk of falls or fractures.
Our study also found several anti-bacterial infection agents were associated with
increased odds of fall-related injury. For example, first-generation cephalosporins
(J01DB) were associated with increasing the odds of fall-related injury by 2.8 times
(aOR=2.79, 99%CI [2.64-2.96]). Users of penicillins with extended spectrum (J01CA)
were 27% more likely to have a fall-related injury than non-users (aOR=1.27, 99%CI
[1.21-1.34]). The findings that some NSAIDs were also positively associated with fallrelated injury indicated that infection itself could have an impact in the occurrence of fallrelated injury. Future research that will take infection into consideration as a confounding
factor might better demonstrate the association between anti-inflammatory and antiinfective agents and fall-related injury in older adults.
It was not expected to see biphosphonates (M05BA), commonly used to treat
osteoporosis, on the list of medications that were associated with increased odds for fallrelated injury (aOR=1.30, 99%CI [1.27-1.33]). This was contrary to Caffarelli et al.
(2017) who found that biphosphonates offer a null or protective effect on falls in older
adults. A possible explanation for this contradictory finding may be that individuals
taking biphosphonates for osteoporosis are more suspectable to fall-related injuries due to
the nature of the medical condition (Kärkkäinen et al., 2010; Uusi-Rasi et al., 2013). We
were unable to tease apart the role of osteoporosis diagnosis in our analysis.
Selective 𝛽-2-adrenoreceptor agonists, also known as bronchodilators, are used as
mainstay treatment for respiratory diseases, such as bronchial asthma and COPD. Mayo
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and colleagues (1989) reported bronchodilators were not associated with increased odds
of falls in hospitals among older adults, but studies examining the association between
bronchodilators and fall-related injury were scarce. In our study, selective 𝛽-2adrenoreceptor agonists were independently associated with fall-related injury
(aOR=1.43, 95% CI [1.39 - 1.47]). The CIHI reported that selective 𝛽-2-adrenoreceptor
agonists were prescribed to 13.1% Ontario older adults in 2016 (CIHI, 2018a), which
makes them a common medication class prescribed to older adults, and continued
investigation into their relation to fall-related injury is necessary.
We noticed that income level (neighborhood income quintile) was not associated with
fall-related injuries in older adults, after adjustments for sex, age group, residence area
(LHINs) and number of medication classes prescribed. Previously, socioeconomic status
was reported to be associated with higher risk of falls and worse outcomes after injuries
(Cruz et al., 2012; Gill et al., 2005; Vieira et al., 2018). It was well-accepted that
individuals with low socioeconomic status had greater difficulty in accessing health
services and consequently prevent factors that could lead to falls (Cruz et al., 2012; Gill
et al., 2005; Vieira et al., 2018). However, similar to our findings, two population-based
studies conducted in different countries (Denmark, Indonesian) did not report the
association between income level and falls or fractures (Bonnerup Vind et al., 2011;
Pengpid et al., 2018). Further, a systematic review investigating the association between
socioeconomic status and osteoporotic fractures did not find that lower income level was
related to higher risk of fractures (Brennan et al., 2009). None of these studies provided
an explanation for the failure to find association between income level and falls or
fractures. In our opinion, the lack of association between the income level and fall-related
injuries could be an indicator of the improving equality of access to health care services
in the general older adult population in Ontario.

3.4.1

Strengths and Limitations

This was a population-based study investigating the association between medication
prescribed within 30 days of fall-related injury in older adults using province-wide
(Ontario) administrative health data. The major strengths are provincial
representativeness and large size with over a million older adults in the case and control
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groups. The dataset included detailed information on demographics, comorbidities,
prescribed medication classes, and strictly defined fall-related injuries using ICD-10-CA
codes. Second, data obtained from IC/ES databases has been recognized to have high
data completeness (Levy et al., 2003) and high quality (Aiken et al., 2016; Liu et al.,
2018; Macri et al., 2017). Third, due to study’s population-based design, the results can
be generalized to the entire population of older adults in Ontario, Canada. Fourth, all the
index events were recorded on the day cases went to the ED because of a fall-related
injury, so recall bias is minimal.
Several limitations are associated with this study. First, the algorithm used to match cases
and controls did not have a fixed ratio and the matching was not successful when groups
were compared on the matching factors. In response, the multivariable logistic regression
modeling was adjusted for the matching variables to account for any residual
confounding. Second, we evaluated only fall-related injuries leading to ED visit,
therefore these results cannot be generalized to less severe fall-related injuries. Third,
only prescribed and dispensed drugs were recorded in ODB database, but neither
prescription nor dispensation can be equated with actual use, which is an unfortunate
limitation of this type of research. Further, we recorded medications prescribed one
month prior to a fall-related injury, but we were not able to ascertain whether a
medication was used for a long-term or it was a new initiation. We believe that the timing
of medication use is of importance and will address this in our future research. Fourth,
some comorbidities might be associated with fall-related injuries, but the detailed
information on indications for prescription was not available in the original databases
from which we extracted our dataset. Hence, our results could include a degree of
overestimation of the association between medications and fall-related injuries. What is
more, confounding by indication was not fully addressed in this study. Confounding by
indication occurs when selecting a particular intervention also affects the outcome
(Kyriacou & Lewis, R, 2016; Salas & Stricker, 1999). For example, patients with more
severe diseases are likely to receive more intensive care and treatment, therefore when
comparing the interventions, the more intensive intervention will appear to result in
poorer outcomes. The degree of severity of a disease affects both treatment selection and
patient outcome and these factors could be related to fall-related injuries. Hence, findings
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from this study should be viewed with caution. Last but not least, there was a lack of
indicators for the frailty in both case and control groups. For example, surgeries and other
medical procedures could substantially but temporarily increase the number of prescribed
medications in the peri-operative period, which in an administrative dataset might be
mimicking the frailty. Unfortunately, in this study, we did not have enough information
to address the impact of frailty on fall-related injuries.

3.5

Conclusion

This study examined the association between fall-related injury in older adults and
medication classes prescribed to them within 30 days prior to the injury. Our findings
acknowledged persistent association of CNS drugs with the fall-related injuries, and
provided additional associations between fall-related injury and statins, PPIs,
antithrombotic agents, laxatives, drugs for benign prostatic hyperplasia, antibiotics,
biphosphonates, and bronchodilators. Well-designed prospective cohort studies probing
into the effects of comorbidities, Injury Severity Scores and detailed prescription
indications are needed to provide more convincing evidence for clinicians and physicians.
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Chapter 4

4

Association between Continuous use or New Initiation
of Medications and Fall-Related Injuries in Older Adults
4.1

Introduction

The rapid growth of world aging population and its related challenges have become
major concern to individuals, families and the societies. It was reported that 20-30% of
community dwelling older adults aged 65 years or older fall every year (Chang et al.,
2010; Tanimoto et al., 2014; Tinetti et al., 2006; Wu & Ouyang, 2017). Falls are the
leading cause of non-fatal and fatal injuries for older adults in many countries and regions
(Bergen et al., 2016; Ellingsen et al., 2018; National Council of Aging, 2018; Public
Health Agency of Canada, 2014). About 30-50% falls result in minor injuries such as
bruises, sprains and strains that may or may not require medical treatment, while 5-10%
of falls lead to serious consequences such as fractures and brain injury (Cameron et al.,
2012; Gillespie et al., 2012; Goldacre et al., 2002; Health Quality Ontario, 2008). Fallrelated injuries can result in decreased independence and quality of life, disability,
prolonged length of stay in hospitals and increased risk of early admissions to long-term
care facilities (Burns et al., 2016; Gill et al., 2013, Scott et al., 2010), as well as cause
substantial economic burden to the public health care system (National Council of Aging,
2018; Parachute, 2015; Zecevic et al., 2012). It was estimated that about 0.9%-1.5% of
total health care cost were the fall-related expenses in the US, Europe and Australia
(Heinrich et al., 2009). Fall-related injuries have become a serious health risk in later life,
that will continue to grow with an increasing older adult population (He et al., 2016).
The mechanism of fall-related injuries in older adults is complicated and multifactorial.
History of falls, old age, mobility and balance problems, and use of psychotropic
medications and cardiovascular medications were reported to be associated with fallrelated injuries (Gillespie et al., 2012; Mccoy et al., 2017; Nilsson et al., 2016). Most
importantly, the prescription of medications to older adults increased significantly over
the last twenty years (Clemens et al., 2015; Craftman et al, 2016; Jackevicius et al., 2009;
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Minard et al., 2016), further increasing this prominent modifiable risk factor for fallrelated injuries.
Previous studies have focused mainly on the association of cross-sectional use of certain
medication classes and fall-related injuries (de Vries et al., 2018; Leipzig et al., 1999a;
Leipzig et al., 1999b; Seppala, Wermelink, et al., 2018; Seppala, van de Glind, et al.,
2018; Zang, 2013). However, medication initiation, change in dosage and long-term use
are significant concerns, as are medications’ therapeutic effects and side effects (Barker
et al., 2004; Engelke et al., 2019; Huybrechts et al., 2011; Hyttinen et al.,2017;
Schmieder et al., 2009). Daoust and colleagues (2018) reported that opioids use were
associated with increasing the risk of falls 2.5 times in first two weeks of drug initiation.
Butt et al. (2013) reported that within 14 days of new initiation of any antihypertensive
drug were associated with doubled risk of falls (Incidence rate ratio [IRR]= 1.94 and 95%
Confidence Intervals [CIs] [1.75-2.16]). A recent systematic review reported that chronic
antihypertensive drug use was not associated with falls, but there was a highly elevated
risk of falls in the first day after the drug initiation (Kahlaee et al., 2018). A clear gap in
the current literature is limited understanding of the association between fall-related
injuries and new initiation or continuous use of medications. The purpose of this study
was to explore the association between chronically used or newly initiated medication
classes and fall-related injury in older adults.

4.2
4.2.1

Methods
Study Design

We conducted a population-based, case-control study using administrative secondary
health care data for Canada’s most populous province of Ontario. Ontario is the largest
province in Canada, with a population of 14.7 million and 2.6 million older adults over
the age of 65 (Statistics Canada, 2020), all of whom have access to universal healthcare
services. The extraction of eligible participants in this study was conducted by IC/ES
analysts, based on a carefully prepared data creation plan (DCP, Appendix B). IC/ES is
an independent, non-profit research institute whose legal status under Ontario’s health
information privacy law allows it to collect and analyze health care and demographic

92

data. IC/ES is a prescribed entity under the section 45 of Ontario’s Personal Health
Information Protection Act. Section 45 authorizes IC/ES to collect personal health
information, without consent, for the purpose of analysis or compiling statistical
information with respect to the management of, evaluation or monitoring of, the
allocation of resources to or planning for all or part of the health system. Projects
conducted under section 45, by definition, do not require review by a Research Ethics
Board. This project was conducted under section 45, and was approved by IC/ES’
Privacy and Legal Office. However, ethics approval for this series of studies was required
in Western University, and it was obtained from the Research Ethics Board at Western
University, London, Ontario, Canada (HSREB #109335, detailed information was
provided in Appendix C).

4.2.2

Data Sources

We used records from three databases held by IC/ES: (1) the Ontario Drug Benefit
(ODB) database, which provides prescription drug coverage data for residents over the
age of 65, including individuals in long-term care homes (Government of Ontario, 2019);
(2) the National Ambulatory Care Reporting System (NACRS), which captures
information on visits to emergency departments (EDs) and community-based ambulatory
care facilities; and (3) the Ontario Registered Persons Database (RPDB), which contains
demographic information for Ontario residents. These databases were linked using
unique encoded identifiers, which ensured the confidentiality of personal and health
information.
Age, sex, residence area (i.e., Local Health Integration Networks [LHINs]), and
neighborhood income quintile were extracted from RPDB dataset. LHINs are the health
authorities that are responsible for the regional public healthcare service in Ontario,
Canada. There are 14 LHINs in operation in Ontario (Local Health Integration Networks,
2020). Neighborhood income quintile is a measure of socioeconomic status that divides
the population living in same dissemination area into five income groups (1 represents
the lowest income; 5 represents the highest income) with approximately 20% of the
population in each group (Canadian Institute for Health Information [CIHI], 2016).
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4.2.3

Selection of Cases and Controls

The cases in this case-control study had to fulfill the following criteria: (a) residing in
Ontario; (b) 66 years and older, (c) visited ED for fall-related injury between January 1,
2010 and December 31, 2014. The ODB program covers the cost of prescription
medications for all Ontarians 65 years and older, therefore those under the age of 66 were
excluded to avoid incomplete medication information in their first year of eligibility.
Patients who visited an ED for fall-related injury were captured by the NACRS database.
The ICD-10-CA codes (CIHI, 2018b; World Health Organization [WHO], 2020) were
used to confirm patients’ diagnosis. Fall-related injury in this study was defined by
combining the ICD-10-CA codes for falls W00-W19, and codes for injury S00-S99 or
T00-T14 (Appendix D). The date when the patient was admitted to the ED due to a fallrelated injury was defined as the index date. For individuals who have had multiple
entries to EDs, only the information of first entry was used. Cases were excluded if they
had experienced an in-hospital fall-related injury, were transferred from another ED, left
the ED without being registered, had a scheduled ED visit or died in ED. Controls were
older adults without a fall-related injury diagnosis extracted from Ontario RPDB, and
matched to cases by the same age, sex, and LHIN, with no fixed ratio. An index date was
assigned randomly to each control within the five-year study period. As the authors had
no access to the database hosted by IC/ES, all of the above operations were completed by
an IC/ES analyst according to a pre-agreed DCP (Appendix B) to generate the matched
dataset, which was then provided to the research team.

4.2.4

Medication Use

Continuous use or new initiation of a medication class prior to fall-related injury was
regarded as one of the risk factors for fall-related injuries. Continuous use of a
medication is operationally defined as more than 90 days of refill of a medication within
three months prior to a fall-related injury. New initiation of a medication is operationally
defined as any new prescription of a medication within 30 days prior to a fall-related
injury. The newly initiated medication must not have appeared in the person’s
prescription list within 365 days to 31 days prior to the injury. ODB datasets uses Drug
Identification Numbers (DIN), an eight-digit number, assigned by Health Canada (Health
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Canada, 2018) to identify different medications. Each DIN included information on
medication’s manufacturer, trade name, active ingredients, strength of the active
ingredients, pharmaceutical form, and route of administration (Health Canada, 2018). In
order to better understand and compare findings of this study with the results of other
studies, DIN codes were converted to Anatomical Therapeutic Chemical (ATC) level 5
codes and grouped into 4th level codes. In ATC classification system, each medication is
classified in a hierarchy with 5 levels (WHO, 2019). The 1 st level includes fourteen
anatomical main groups, these main groups are divided into 2 nd level, which is the
pharmacological or therapeutic group. The 3 rd and 4th levels are chemical,
pharmacological or therapeutic subgroups and the 5 th level the chemical substance. ATC
4th level was used to report continuous use and new initiation of different medications
because it is the level which aggregates medications just above their descriptive chemical
substance (Krause, 2008).

4.2.5

Statistical Analysis

The difference between case and control groups in characteristics such as age, sex,
income quintile, LHINs, the number of medication classes prescribed with, presence of
COPD, asthma, dementia, diabetes and hypertension were evaluated by Wilcoxon rank
sum test, with an alpha of .01. Older adults were categorized into three groups, aged 6674, 75-84, and 85+. The number of medication classes prescribed to each older adult
within 30 days of the fall-related injuries was calculated and classified into one of four
categories: 0-4, 5-9, 10-14, and 15 or more different medication classes. Number of
continuous users and new users of each medication class in both case and control group
were calculated. To ensure the power, only top 30 most frequent medication classes for
continuous use and for new initiation were included in the regression analysis. Univariate
logistic regression was used to calculate the crude Odds Ratios (ORs) and 99%
confidence intervals (CIs) for continuous use or new initiation of each medication class.
Multivariate logistic regression models were conducted for each included medication
class, adjusted for sex, age group, LHIN, neighborhood income quintile, and number of
medication classes prescribed. The corresponding ORs were recorded as adjusted ORs
(aORs). All the analysis was conducted with SAS 9.4 (SAS Institute, 2013).
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4.3

Results

This study included 1,005,066 community-dwelling older adults. The case group
included 255,270 older adults who experienced fall-related injuries over the five-year
period. The mean age of the cases was 77.7±7.7 years and 61.1% were female. The
control group included 749,796 older adults, with a mean age of 75.1±7.5 years old and
54.0% female. The case and control groups were similar in income quintile distribution
but were significantly different in LHINs, age group constitution, female percentage, and
number of prescribed medication classes (Table 3.1).
For medication classes with continuous use, HMG-CoA reductase inhibitor (statin,
C10AA) was the most commonly prescribed among older adults who experienced fallrelated injuries (Table 4.1). Eight different anti-hypertensive medications were among the
top 30 medication classes with most common continuous use. Continuous use of
psychotropic agents such as antidepressants (N06AB and N06AX), benzodiazepine
derivatives (N05BA), opioids (N02AA) and anticholinesterases (N06DA) were also very
common. Other medications with continuous use were proton pump inhibitors (A02BC),
laxatives (A06AA), glucose sugar lowering drugs (A10BA, A10BB), thyroid hormones
(H03AA) and biphosphonates (M05BA). After adjustment for sex, age group, number of
medications prescribed, income quintile and residence area (LHINs), continuous use of
selective serotonin reuptake inhibitors (SSRIs, medication for depression) were
associated with increasing the odds of fall-related injuries almost by two times
(aOR=1.96, 99%CI [1.91-2.01]). Other medications that could increase the odds of fallrelated injuries by over 50% were drugs for benign prostate hyperplasia (G04CA and
G04CB), antithrombin agents (B01AC) and anticholinesterases (N06DA) for treating
Alzheimer’s disease. Organic nitrates (C01DA) and H2-receptor antagonist (lowering the
production of stomach acid) were negatively related to fall-related injuries.
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Table 4.1 Association Between Top 30 most Common Medications with Continuous Use and Fallrelated Injury in Older Adults
ATC code Medication Class
A02BA
A02BC
A06AA
A10BA
A10BB
B01AA
B01AC
B03AD
C01DA
C03AA
C03CA
C07AB
C08CA
C08DB
C09AA
C09CA
C09DB
C10AA
C10AX
G04CA
G04CB
H03AA
M04AA
M05BA
N02AA
N05BA
N06AB
N06AX
N06DA
R03BB

H2-receptor antagonists
Proton pump inhibitors
Softeners, emollients
Biguanides
Sulfonylureas
Vitamin K antagonists
Platelet aggregation inhibitors
Iron in combination with folic acid

Organic nitrates
Thiazides, plain
Sulfonamides, plain
Beta blocking agents, selective
Dihydropyridine derivatives
Benzothiazepine derivatives
ACE inhibitors, plain
Agents on RAS
ARBs and CCBs
HMG CoA reductase inhibitors
Other lipid modifying agents
Alpha-adrenoreceptor
antagonists
Testosterone-5-alpha reductase
inhibitors
Thyroid hormones
Preparations inhibiting uric acid
production
Biphosphonates
Natural opium alkaloids
Benzodiazepine derivatives
SSRIs
Other antidepressants
Anticholinesterases
Anticholinergics

Number of Users
Case
Control Total
5,343 13,837 19,180
48,280 86,250 134,530
9,810 13,810 23,620
23,371 53,109 76,480
12,073 27,299 39,372
9,422 16,677 26,099
12,938 19,568 32,506
7,720 12,699 20,419
6,744 14,738 21,482
23,513 58,028 81,541
21,463 39,165 60,628
42,537 92,690 135,227
38,097 88,173 126,270
10,318 18,718 29,036
48,459 117,654 166,113
26,181 60,570 86,751
7,274 19,629 26,903
85,971 195,116 281,087
7,930 15,842 23,772

Unadjusted ORs
(99% CIs)

Adjusted ORs*
(99% CIs)

1.14 [1.10, 1.17]
1.97 [1.65, 2.34]
2.13 [2.08, 2.19]
1.32 [1.30, 1.34]
1.31 [1.29, 1.34]
1.69 [1.64, 1.73]
1.99 [1.95, 2.04]
1.81 [1.76, 1.86]
1.35 [1.32, 1.39]
1.21 [1.19, 1.23]
1.67 [1.64, 1.70]
1.42 [1.40, 1.44]
1.35 [1.33, 1.37]
1.65 [1.61, 1.69]
1.26 [1.24, 1.27]
1.30 [1.28, 1.32]
1.09 [1.06, 1.12]
1.44 [1.43, 1.46]
1.49 [1.45, 1.53]

0.87 [0.83, 0.91]
1.40 [1.38, 1.42]
1.37 [1.32, 1.42]
1.17 [1.15, 1.20]
1.12 [1.09, 1.16]
1.22 [1.18, 1.26]
1.56 [1.51, 1.61]
1.19 [1.14, 1.23]
0.78 [0.75, 0.81]
1.10 [1.08, 1.13]
N/A
1.18 [1.16, 1.20]
1.15 [1.13, 1.17]
1.34 [1.29, 1.38]
1.10 [1.09, 1.12]
1.17 [1.15, 1.20]
1.13 [1.09, 1.17]
1.37 [1.35, 1.39]
1.45 [1.40, 1.50]

13,440

27,968

41,408 1.44 [1.41, 1.47]

1.40 [1.36, 1.44]

6,811

12,494

19,305 1.62 [1.57, 1.67]

1.66 [1.59, 1.73]

69,421 103,972 1.53 [1.51, 1.56]

1.25 [1.23, 1.28]

34,551
8,050

17,818

25,868

16,170
7,693
13,724
20,475
16,001
11,194
9,885

32,050
11,281
24,991
24,259
21,066
12,913
17,933

48,220
18,974
38,715
44,734
37,067
24,107
27,818

1.34 [1.30, 1.37]
1.52 [1.49, 1.55]
2.04 [1.98, 2.10]
1.65 [1.61, 1.68]
2.61 [2.56, 2.66]
2.31 [2.27, 2.36]
2.62 [2.55, 2.69]
1.65 [1.60, 1.69]

1.19 [1.14, 1.23]
1.19 [1.16, 1.22]
1.34 [1.29, 1.40]
1.18 [1.14, 1.21]
1.96 [1.91, 2.01]
1.62 [1.57, 1.67]
1.58 [1.52, 1.64]
1.27 [1.22, 1.31]

Note ACE inhibitors: angiotensin converting enzyme inhibitors; RAS: renin-angiotensin system;
ARBs: Angiotensin II receptor blockers; CCBs: calcium channel blockers; N/A: not available
* adjusted for sex, age group, income quintile, residence area (Local Health Integration Networks)
and number of medication classes prescribed in 30 days
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Table 4.2 Association between Top 30 New Initiated Medication Classes and Fall-related Injury
ATC
code
A02BC
A06AA
A06AB
A06AD
B03AD
C01DA
C03CA
C07AB
C08CA
C09AA
C09CA
C10AA
H02AB
J01CA
J01DB
J01DC
J01FA
J01MA
J01XE
M01AB
M01AE
N02AA
N05BA
N06AB
N06AX
R03BA
R03BB
R03CC
S01AA
S01BA

Number of Users
Case Control Total
2,010
4,255 6,265
Proton pump inhibitors
1,650
2,559 4,209
Softeners, emollients
1,555
2,348 3,903
Contact laxatives
1,840
2,789 4,629
Osmotically acting laxatives
804
1,501 2,305
Iron in combination with folic acid
913
1,947 2,860
Organic nitrates
1,236
2,103 3,339
Sulfonamides, plain
953
1,719 2,672
Beta blocking agents, selective
758
1,674 2,432
Dihydropyridine derivatives
938
2,046 2,984
ACE inhibitors, plain
660
1,431 2,091
agents on the renin-angiotensin system
1,106
2,562 3,668
HMG CoA reductase inhibitors
2,542
4,921 7,463
Glucocorticoids
2,385
4,869 7,254
Penicillins with extended spectrum
1,951
2,750 4,701
First-generation cephalosporins
631
1,389 2,020
Second-generation cephalosporins
1,945
4,358 6,303
Macrolides
2,931
5,296 8,227
Fluoroquinolones
1,410
2,093 3,503
Nitrofuran derivatives
Acetic acid derivatives, related
747
1,367 2,114
substances
1,083
1,863 2,946
Propionic acid derivatives
4,409
6,515 10,924
Natural opium alkaloids
1,523
2,653 4,176
Benzodiazepine derivatives
1,247 2,579
Selective serotonin reuptake inhibitors 1,332
1,417
1,417 2,834
Other antidepressants
750
1,815 2,565
Glucocorticoids (drugs for COPD)
701
1,316 2,017
Anticholinergics
Selective beta-2-adrenoreceptor
1,757
2,466 4,223
agonists
672
1,438 2,110
Antibiotics-ophthalmologicals
985
2,133 3,118
Corticosteroids, plain
Medication Class

Unadjusted ORs
(99% CIs)
1.39 [1.32, 1.47]
1.90 [1.79, 2.02]
1.95 [1.83, 2.08]
1.95 [1.84, 2.07]
1.58 [1.45, 1.72]
1.38 [1.27, 1.49]
1.73 [1.61, 1.86]
1.63 [1.51, 1.77]
1.33 [1.22, 1.45]
1.35 [1.25, 1.46]
1.36 [1.24, 1.49]
1.27 [1.18, 1.36]
1.52 [1.45, 1.60]
1.44 [1.37, 1.52]
2.09 [1.98, 2.22]
1.34 [1.22, 1.47]
1.31 [1.25, 1.39]
1.63 [1.56, 1.71]
1.99 [1.86, 2.13]

Adjusted ORs*
(99% CIs)
1.08 [1.01, 1.16]
1.26 [1.16, 1.37]
1.30 [1.19, 1.42]
1.32 [1.22, 1.43]
N/A
0.91 [0.82, 1.01]
N/A
1.15 [1.04, 1.28]
N/A
N/A
1.45 [1.15, 1.84]
1.11 [1.01, 1.22]
1.17 [1.10, 1.25]
1.24 [1.16, 1.33]
1.56 [1.44, 1.69]
N/A
1.08 [1.01, 1.16]
1.13 [1.06, 1.20]
1.40 [1.28, 1.54]

1.61 [1.47, 1.76] 1.50 [1.33, 1.70]
1.71 [1.59, 1.85]
2.01 [1.93, 2.09]
1.69 [1.59, 1.80]
3.15 [2.91, 3.40]
2.94 [2.73, 3.17]
1.21 [1.12, 1.32]
1.57 [1.43, 1.72]

1.53 [1.38, 1.70]
1.58 [1.50, 1.67]
1.17 [1.08, 1.28]
2.14 [1.93, 2.38]
1.94 [1.76, 2.15]
0.89 [0.80, 1.00]
N/A

2.10 [1.98, 2.24] 1.49 [1.37, 1.62]
1.37 [1.25, 1.51] N/A
1.36 [1.26, 1.47] 1.17 [1.06, 1.30]

Note. ACE inhibitors: angiotensin converting enzyme inhibitors; COPD: chronic obstructive
pulmonary disease; N/A: not available
* adjusted for sex, age group, income quintile, residence area (Local Health Integration Networks)
and number of medication classes prescribed in 30 days
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Natural opium alkaloids (opioids) were the most commonly new-initiated medications in
older adults before they had fall-related injuries. Anti-hypertensive agents and
psychotropic agents were also very common. Interestingly, there were six different
medications for treatment of infections in the top 30 most commonly new-initiated
medications (Table 4.2). New initiation of SSRIs and other antidepressants were
associated with increasing the odds of fall-related injuries by more than two times
(SSRIs: aOR=2.14, with 99%CI [1.93-2.38]; other antidepressants: aOR=1.94 with
99%CI [1.76-2.15]). New initiation of opioids (N02AA), first-generation cephalosporins
(J01DB), propionic acid derivatives (M01AE), and acetic acid derivatives (M01AB) were
also associated with increasing the odds of fall-related injuries by over 50%. Except for
agents acting on renin-angiotensin system (C09CA), new initiation of other
antihypertensive showed no association or minor association with fall-related injuries.

4.4

Discussion

This population-based, case-control study evaluated the association between fall-related
injuries and 30 most common medication classes for continuous use and medications that
were newly initiated. Continuous use of antidepressants, drugs for benign prostate
hyperplasia, anticholinesterases for Alzheimer’s disease, emollients for constipation, and
antithrombin agents were found to increase the odds of fall-related injuries by over 50%.
New initiation of antidepressants, opioids, first-generation cephalosporins, non-steroids
anti-inflammatory drugs (NSAIDs), and laxatives also showed to be associated with
increased odds for fall-related injuries.
There is no consensus among researchers on how to define continuous use of a
medication as it depends on the medication itself. For example, for antibiotics and
NSAIDs, more than 14 days of use is considered as long-term. For benzodiazepines and
antidepressants, six months is considered as long-term use (Cartwright et al., 2016;
Kurko et al., 2015). However, for blood glucose lowering agents and antihypertensive
drugs, a year is considered as long-term use (Kahlaee et al., 2018). Older adults
diagnosed with chronic diseases often take medications for years and even remaining
lifetime (Lornstad et al., 2019; Rossello et al., 2015, Sharma et al., 2015). This study
applied three months (90 days) period to define “continuous use” of medications, guided
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by acceptance of this definition in previous studies (Ammerman et al., 2019; Aubron et
al., 2010; Bargagli et al., 2019; Hart et al., 2019)
Statins are widely prescribed to older adults with high cholesterol in order to reduce the
risk of cardiovascular event. In our study, 28.1% older adults used statins for a long-term
of over three months. This rate was comparable to findings of Wang et al. (2016) who
reported a chronic statin use rate in 31.4% older adults. The association between
continuous use of statins and continuous use odds of fall-related injuries in older adults
was unexpected (aOR=1.37, 99%CI [1.35, 1.39]). Some clinical trials demonstrated that
statins had a decreased survival benefit in sicker patients, especially among older adults
with heart failure (Kjekshus et al., 2007) and those undergoing dialysis (Wanner et al.,
2005). However, a systematic review summarized three studies on statin use as an
exposure to the risk of falls (Seppala, van de Glind, et al., 2018), and reported a pooled
OR of 0.80 (95%CI [0.65,0.98]). The authors explained that statins’ protective
association with falls might be explained by statins’ reducing white matter lesion
progression, thus delaying the balance impairments. However, this meta-analysis did not
take into consideration the duration of statin use, so further research was recommended
on the statin use duration in older adults and better differentiation of participants (e.g.,
different age groups or health status). Important distinction here is that our study reports
association with injuries due to falls, not falls themselves.
Proton pump inhibitors (PPIs) were prescribed to 32.1% of Canadian older adults in 2016
(CIHI, 2018b). Although we did not find that new initiation of PPIs were associated with
increased odds of fall-related injuries, continuous use of PPIs was identified to be
associated with increasing the odds of injury by 40% (aOR=1.40, 99%CI [1.38-1.42]).
Lewis et al. (2014) reported that PPI therapy for longer than one year was associated with
continuous use odds of hip fracture in older adults (aOR=2.04, 95%CI [1.23-3.37]). Yang
et al. (2006) showed that the strength of the association continuous use with increasing
duration of PPI therapy (1 year of PPI therapy aOR=1.22, 95% CI, [1.15-1.30]; 2 years,
aOR=1.41, 95% CI, 1.28-1.56]; and 4 years, 1.59 [95% CI, 1.39- 1.80]; P.001 for all
comparisons). A possible explanation for why PPIs increase the risk of fracture might be
that PPIs reduce intestinal calcium and vitamin D absorption and thus might contribute to
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a decrease in bone mineral density (Dharmarajan et al., 2008). Another mechanism might
lie in the fact that PPI users were found to have a 18% lower level of Vitamin B12.
Ample evidence shows that long-term Vitamin B12 deficiency could result in gait
disorders, muscle weakness, cognitive decline and impaired vision (Lewis et al., 2014;
Marcuard et al., 1994; Stabler, 2013), all of which are risk factors for fall-related injuries.
Although researchers have noticed that initiation or continuous use of antihypertensive
agents were related to falls, studies on the association with fall-related injuries remain
rare. A systematic review using more than 28 days of medication therapy as continuous
use reported that continuous use of antihypertensive agents did not increase the risk of
falls in older adults (Kahlaee et al., 2018). But our study showed that continuous use of
angiotensin-converting enzyme inhibitors (ACEIs), BBs, dihydropyridine derivatives,
agents acting on the renin-angiotensin system, thiazides, angiotensin II receptor blocker
(ARBs) and calcium channel blockers (CCBs) combination were associated with slightly
increasing the risk of fall-related injuries. Continuous use of benzothiazepine derivatives
were associated with increasing the odds of fall-related injuries by 34% (aOR=1.34,
99%CI [1.29-1.38]).
The Kahlaee et al. (2018) systematic review also reported that new initiation of diuretics,
BBs, CCBs, and ACEI/ARBs were associated with increased the risk of falls. Another
population-based study using ODB database to explore the new initiation of
antihypertensive agents reported that the risk of falls in older adults increased within the
period of 45 days after new initiation of diuretics, ACEIs, ARBs, CCBs and BBs (Butt et
al., 2013). The same group of researchers demonstrated that initiation of BBs and ACEIs
were associated with increased risk of hip fractures in older adults (BBs: aOR=1.58,
95%CI [1.01-2.48]; ACEIs: aOR=1.53, 95%CI [1.12-2.10]), which was in line with our
results (Butt et al., 2012). Our findings identified that new initiation of beta-blocking
agents (BBs) were only associated with a slightly increased risk of fall-related injuries
(aOR=1.15, 99%CI [1.04-1.28]), while new initiation of agents on the renin-angiotensin
system were associated with increasing the odds by 45% (aOR=1.45, 99%CI [1.151.84]). The findings of our study provided new evidence on the association between
continuous use or new initiation of antihypertensive drugs and fall-related injuries in
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older adults, identifying the need for additional studies to improve the knowledge in the
future.
In addition, our findings showed that continuous use of psychotropic agents such as
selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs) and
anticholinesterases for treating Alzheimer’s disease in older adults were associated with
increasing fall-related injuries odds by 60-96%. Continuous use of opioids also was
associated with increasing the odds by 34% (aOR=1.34, 99%CI [1.29-1.40]). New
initiation of SSRIs and TCAs were associated with increasing the odds of fall-related
injuries almost by two times, while continuous use and new initiation of benzodiazepines
was only slightly associated with increased risk of fall-related injuries. The association
between psychotropic agents and falls, and fall-related injuries in older adults has been
studied extensively. A wide range of psychotropic medications such as analgesics,
antiepileptics, antidepressants, sedatives and hypnotics have been confirmed to relate to
fall-related injuries (Gray et al., 2020; Seppala, Wermelink, et al., 2018; Seppala, van de
Glind, et al., 2018), but few studies focused on the association between the time window
of using a medication and fall-related injuries. Our study findings were consistent with
Vitry and colleagues (2010), who reported that persistent use of psychotropic medications
in female older adults was associated with increasing the risk of experiencing hip fracture
by 2.5 times (RR=2.54, 95%CI [1.57-4.11]). Using medication information from ODB
database, Liu et al. (1998) reported that new initiation of SSRIs in older adults was
associated with increasing the odds of hip fracture by 2.4 times (aOR=2.4, 95%CI [2.02.7]), and new initiation of tertiary-amine TCAs were associated with increasing the odds
of hip fracture by 50% (aOR=1.5, 95%CI [1.3-1.7]). Findings from our study not only
indicated that new initiation of SSRIs and TCAs were related to fall-related injuries, but
also that continuous use of SSRIs and TCAs could be associated with increased odds of
fall-related injuries.
Very few studies focused on continuous use or new initiation of medication classes other
than psychotropic agents or antihypertensive agents. Findings from our study, that
continuous use of two medication classes for treatment of benign prostate hyperplasia
(G04CA and G04CB), anti-thrombotic agents (B01AA and B01AC) and emollients for
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constipation (A06AA) was associated with increased risk of fall-related injuries made an
original contribution to the current knowledge. Our study also showed that new initiation
of some laxatives (A06AA, A06AB and A06AD), antibiotics (J01CA, J01DB and
J01XE), NSAIDs (M01AB and M01AE) and selective beta-2-adrenoreceptor agonists
could increase the risk of fall-related injuries by 30-50%. Further studies need to adjust
for indications for these medications to provide further evidence on their association with
fall-related injuries in older adults.
Most previous studies ascertained medication use in older adults at the baseline or at the
time of fall or fall-related injuries, without information on whether the medication was
newly initiated or has been used for a long-term (Leipzig et al., 1999a; Leipzig et al.,
1999b; Seppala, Wermelink, et al., 2018; Seppala, van de Glind, et al., 2018). Findings
from our study provided evidence about a “window” of opportunity to incorporate
preventive strategies such as education or closer monitoring over a specific time in the
pharmacotherapy process.

4.4.1

Strengths and Limitations

The major strengths of this population-based study are provincial representativeness and
large size of over a million observations in case and control groups of older adults.
Second, the data obtained from IC/ES databases had satisfying data completeness (Levy
et al., 2003) and high quality as reported consistently in previous studies (Aiken et al.,
2016; Liu et al., 2018; Macri et al., 2017). Third, due to study’s population-based design,
the results can be generalized to the entire population of older adults in Ontario, Canada.
Fourth, the recall bias is minimal as all the fall-related injuries were recorded on the day
cases presented to the ED.
Several limitations are associated with this study. First, the controls were matched with
cases by sex, age and residence area (LHIN), but as the matching ratio was not fixed,
resulting in great imbalance between the case and control group (Table 3.1). We adjusted
for sex, age group, residence area (LHIN), income quintiles and number of medication
classes prescribed, in regression analysis so that these imbalances were considered.
Second, only prescribed and dispensed drugs were recorded in ODB database, but
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chronic comorbidities and aging-related reduction in cognitive function could lead to low
adherence to prescribed medications in older adults (Hennein et al., 2018). Hence, neither
prescription nor dispensation can be equated with actual use. Third, some comorbidities
might be associated with fall-related injuries, but the detailed information on indications
for prescription was not available in the original dataset. Hence our results could include
a degree of overestimation of the association between medication and fall-related injuries.
What is more, confounding by indication (Kyriacou & Lewis, R, 2016; Salas & Stricker,
1999) was not fully addressed in this study. For example, patients with more severe
diseases are likely to receive more intensive care and treatment and when comparing the
interventions, the more intensive intervention will appear to result in poorer outcomes.
Hence, findings from this study should be viewed with caution. Fourth, there was a lack
of indicators on the frailty for both case and control group. For example, surgeries and
other medical procedures could increase the frailty, accompanied by an obvious
increasing in the number of medications prescribed during the peri-operation period. But
in this study, we did not have enough information to address the impact of frailty on fallrelated injuries.

4.5

Conclusion

This study examined the association between fall-related injuries in older adults and
continuous use or new initiation of medication classes prior to the injury. Findings
revealed that both continuous use and new initiation of particular medication classes were
associated with fall-related injuries. Namely, continuous use of antidepressants, drugs for
benign prostate hyperplasia, anticholinesterases for Alzheimer’s disease, emollients for
constipation and antithrombin agents were found to increase the risk of fall-related
injuries. New initiation of antidepressants, opioids, first-generation cephalosporins, nonsteroids anti-inflammatory drugs, and laxatives showed to be associated with increased
risk for fall-related injuries. This evidence suggests existence of a “window” of
opportunity for application of injury prevention strategies while closely monitoring
timing in the process of pharmacotherapy. Future research should consider exploration of
comorbidities and particular indications for prescription to provide more convincing
evidence on the association of medication and fall-related injuries in older adults.
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Chapter 5
Discussion

5

5.1

Main findings

The main purpose of this dissertation was: 1) to provide a comprehensive list of
medication classes prescribed to older adults within one year prior to their fall-related
injuries, 2) to evaluate the association between fall-related injuries and most frequently
prescribed medication classes prescribed within 30 days prior to the injuries, and 3) to
explore association between chronically used and newly initiated medications and fallrelated injury in older adults.
Study 1, was descriptive to set the stage and help determine research questions for
consecutives studies. Findings alerted us to the difference between the medication classes
prescribed to older adults who experienced the fall-related injury and the medication
classes prescribed to the general population of older adults. To explore further, in Study
2, we established case control group, recorded the medication classes prescribed to both
groups, and conducted logistic regression to find out which medications were positively
related to fall-related injury. Through this project, we recognized the importance of
initiation and duration of medication use in relation to the fall-related injury. Hence, in
Study 3, we explored whether the medication classes were prescribed for a long-term or
were initiated within one month prior to the injury. The associations between continuous
use or new initiations and fall-related injury were identified by multivariate logistics
regression.
The main findings are briefly summarized as follows:
•

Among older adults sustaining any fall-related injury, 48.5% were prescribed
statins, 34.3% proton pump inhibitors (PPIs), 29.0% angiotensin converting
enzyme inhibitors (ACEIs), 25.0% opioids, 16.6% benzodiazepine derivatives,
and 14.7% selective serotonin receptor inhibitors (SSRIs) within one year prior to
the injury. (Study 1)
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•

Similar patterns of medication prescription were found for fall-related fractures
and traumatic brain injury. Among older adults who had fall-related fracture,
45.4% were prescribed statins, 33.1% PPIs, 27.6% ACEIs, 24.5% opioids and
14.6% SSRIs. Among older adults who had fall-related traumatic brain injury,
52% were prescribed statins, 35.5% PPIs, 30.3% ACEIs, 24.9% opioids and
16.5% SSRIs. (Study 1)

•

More than third, 36.4%, of older adults were prescribed 5-9 different medication
classes and 41.2% were prescribed 10 or more medication classes within one year
prior to fall-related injury. (Study 1)

•

Consistent with previous studies, we reported that use of laxatives, psychotropic
agents and anti-inflammation drugs within one month prior to an injury can
increase the odds of fall-related injury in older adults. (Study 2)

•

Relatively new to the current knowledge is that we identified that statins, drugs
for benign prostatic hyperplasia, biphosphonates, penicillins with extended
spectrum, and bronchodilators also were associated with increased risk of fallrelated injury. (Study 2)

•

After adjusting for sex, age group, income level, residence area and number of
medications prescribed, continuous use (more than 90 consecutive days) of
statins, PPIs, SSRIs, 𝛼-adrenoreceptor antagonists, platelet aggregation inhibitors
and anticholinesterases was associated with increasing the odds of fall-related
injury in older adults by nearly 50%. (Study 3)

•

After adjusting for sex, age group, income levels, residence area and number of
medications prescribed, new initiation (starting a medication within one month
prior to a fall-related injury) of opioids, first-generation cephalosporins, selective
𝛽2-adrenoreceptor agonists, SSRIs and other antidepressants (mostly tricyclic
antidepressants [TCAs]) was associated with increasing the odds of fall-related
injury in older adults by 50%. (Study 3)

It is well established that medications are modifiable risk factors for falls and fall-related
injuries (de Vries et al., 2018; Leipzig et al., 1999a; Leipzig et al., 1999b; Seppala,
Wermelink et al., 2018; Seppala, van de Glind et al., 2018; Woolcott et al., 2009).
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Previous studies reporting medication use in Canadian older adults mainly focused on a
specific medication class, such as benzodiazepines (Kassam et al., 2006),
antihypertensive medications (Verma et al., 2018), antihyperglycemic medications
(Clemens et al., 2015), statins (Minard et al., 2016) and opioids (Sharma et al., 2019),
already suspected to contribute to fall-related injuries. Very few studies were broader in
scope and provided an overview of medication use in older adults before they had fallrelated injuries. That is why the Study 1 investigated patterns of medications prescribed
to older adults within one year prior to a fall-related injury. With this new knowledge we
are now able to explore the difference in medication use between older adults who
experienced fall-related injuries and the community dwelling older adults. We chose oneyear lookback window to make Study 1 comparable to CIHI report in 2018 because CIHI
published a report on medications prescribed to the general population of Canadian older
adults within the year of 2016 (CIHI, 2018). Compared to the findings for general older
adults in Ontario in CIHI 2018 report, a higher percentage of older adults who have
experienced fall-related injury were prescribed with ACEIs (26.2% vs. 29.0%), BBs
(23.3% vs. 25.9%), opioids (15.4% vs. 25.0%), biphosphonates (9.4% vs. 20.4%),
benzodiazepine derivatives (10.4% vs. 16.1%), thiazides (15.2% vs. 10.8%) and SSRIs
(10.5% vs. 14.7%). All these medication classes (except for biphosphonates) were
previously included in the FRIDs lists (Bauer et al., 2012; the Swedish National board of
Health and Welfare, 2010; Winter et al., 2016; Zia et al., 2017), which partly supported
the that these medications were associated with fall-related injuries. Another major
difference was polypharmacy, of the number of medication classes prescribed within the
past year.
The effects of polypharmacy have been repeatedly cited in literature as detrimental due to
potential for adverse drug reactions and drug-drug interactions, especially with decline in
hepatic and renal function in aging bodies (Chen et al., 2014; Chung, 2014; Huang et al.,
2012; Rowe, et al., 1976; Tan et al., 2015). According to CIHI report, 39.4% older adults
were prescribed 5 to 9 different medication classes and 26.5% were prescribed with 10 or
more different medication classes within the year of 2016. Our Study 1 showed that
36.4% of older adults who experienced fall-related injury were prescribed 5-9 different
medication classes and 41.2% were prescribed 10 or more different medication classes
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within the year prior to the injury. It is impossible to confirm in both studies if these
medications were prescribed concurrently, nonetheless, the higher number of medication
classes used by injured older adults is concerning and requires further exploration.
Associations between medication classes commonly prescribed such as statins, PPIs,
biphosphonates, antibiotics and fall-related injuries in older adults has not been well
established (de Vries et al., 2018; Seppala, van de Glind, et al., 2018). Most previous
studies strictly selected study participants which confined the generalizability of their
findings. Our Study 2 was a population-based, case-control study which is
methodologically comparable to the Canadian study by Kelly et al. (2003) and Swedish
study by Kuschel et al (2015). Both studies were population-based and used
administrative data to identify a wide range of medication classes associated with fallrelated injury in older adults. Both studies captured medication prescription within 30
days prior to the fall-related injury. Kelly et al. (2003) used 1997/1998 fiscal year health
registry data from Alberta, Canada. However, the two studies differ in the adjustments for
cofounders. Kelly et al. (2003) used sex, age, income, seventeen different medications
and seventeen different comorbidities (e.g., eye disorder, nutritional deficiencies,
hypertension, depression, dementia, incontinence, etc.) as confounding factors. They
found that only narcotic pain killers, anti-convulsants (anti-epileptics), and antidepressants were independently associated with an increased risk of sustaining injurious
falls. The authors acknowledged that taking so many comorbidities into consideration
was complicated because multiple medication classes could be used in the treatment of
one comorbidity, while a single medication class could be used to treat multiple
comorbidities. The real effect of every single medication class on fall-related injuries is
difficult, if not impossible, to fully address. That is partly the reason why we chose to not
to take five comorbidities we had data for into consideration as confounders. Instead, we
used the number of medication classes as an indicator for the possible number of
comorbidities. The second study, by Kuschel and colleagues (2015), reported twenty
most commonly prescribed ATC 3rd medication classes and their association with fallrelated injuries using Swedish public health data. They reported that CNS drugs (N02A,
N02B, N05C and N06A), drugs for peptic ulcer (A02B), constipation drugs (A06A),
antithrombotic agents (B01A), Vitamin B12 (B03B), Calcium (A12A), and NSAIDs
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(M01A) were independently associated with fall-related injuries. Consistent with their
results, our Study 2 found (at ATC 4th level) a positive association between PPIs
(A02BC), constipation drugs (A06AA, A06AB), anti-thrombotic agents (B01AC,
B01AE), and NSAIDs (M01AB, M01AE, and M01AH) and fall-related injury. Relatively
new contribution to the current knowledge from our study are additional medication
classes such as lipid-lowering agents (statins, C10AA), drugs for benign prostatic
hyperplasia (G04CA and G04CB), pennicillins with extended spectrum (J01DB),
biphosphonates (M05BA), and selective 𝛽-2-adrenoreceptor agonists for asthma
(R03CC) that were positively associated with fall-related injuries in older adults.
Pharmacologically, it is plausible that statins and drugs for benign prostatic hyperplasia
could increase the risk of fall-related injuries because these medications were reported to
induce muscle disorders and cardiovascular side effects such as orthostatic hypotension
(Curfman, 2017; Lee & Cho, 2018; Sica, 2005). Mechanisms of how antibiotics,
bisphosphonate and bronchodilators can lead to fall-related injuries need to be explored
further. Collectively, these studies provide evidence that clinicians should not
underestimate the risk of fall-related injuries when prescribing some of the most frequent
medications to older adults.
Starting a new medication, changing a dosage, or prescribing a medication for a very
long-term use are significant concerns in pharmacotherapy, as medications’ therapeutic
effects and side effects are closely related to the initiation and duration of medication use
(Barker et al., 2004; Engelke et al., 2019; Huybrechts et al., 2011; Hyttinen et al.,2017;
Schmieder et al., 2009). To explore the association between medication classes and fallrelated injuries, Study 3 identified top 30 most commonly prescribed medications as new
initiations and for continuous use. Consistent with previous studies (Kahlaee et al., 2018;
Vitry et al., 2010; Yang et al., 2006), continuous use of antihypertensives, antidepressants
and proton pump inhibitors (PPIs) were reported to increase the risk of fall-related
injuries. New initiation of antihypertensives and antidepressants was also associated with
higher risk of fall-related injuries. What emerged as novel in our findings, was that
continuous use of two medication classes (G04CA and G04CB) for treatment of benign
prostate hyperplasia, anti-thrombotic agents (B01AA and B01AC) and emollients for
constipation (A06AA) were also associated with inceasing the risk of fall-related injuries.
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For new initiations, our study showed that some laxatives (A06AA, A06AB and
A06AD), antibiotics (J01CA, J01DB and J01XE), NSAIDs (M01AB and M01AE) and
selective beta-2-adrenoreceptor agonists could increase the risk of fall-related injuries by
30-50%. The findings from Study 3 provided evidence about a “window” of opportunity
for implementation of injury prevention strategies for older adults such as education or
closer monitoring over a specific time in the pharmacotherapy process.
The findings of these studies provide clear evidence to support better clinical decisions to
the family doctors, physicians, geriatricians, pharmacists and other health care
professionals on association between medication classes and fall-related injury in older
adults. Previous studies focused predominantly on psychotropic medications and
antihypertensive agents and their mechanisms on inducing falls in older adults, while our
studies reported additional medication classes that might be associated with the
occurrence of fall-related injuries in older adults, such as statins, PPIs, biphosphonates,
bronchodilators and antibiotics. These medication classes are also among the most
extensively prescribed ones, so their impact on fall-related injuries should not be
underestimated or ignored.

5.2

Clinical Implications and Knowledge Translation

The main part of this thesis focused on identifying medication classes as risk factors for
fall-related injuries in older adults. This purpose was in line with World Health
Organization (WHO) falls prevention strategy on improving the identification and
assessment of determinants of falls (WHO, 2007) and the Canadian Patient Safety
Institute’s (CPSI) injury reduction strategy on multifactorial risk assessment and
individualized interventions for those at high risk of fall-related injuries. In our extensive
study of medication classes that were associated with fall-related injuries, we identified
several commonly prescribed medication classes that might contribute to fall-related
injuries in older adults. In addition to psychotropic agents and medications for
cardiovascular system disease, other medications such as laxatives, antithrombotic
agents, antibiotics and bronchodilators were also reported to increase the risk of fallrelated injuries (Study 2). The impact of these medication classes on fall-related injuries
was rarely studied, yet they are frequently prescribed to older adults. Findings from this
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thesis provide evidence to family doctors, physicians, geriatricians and pharmacists to
support their informed decisions about deprescribing or balancing benefits and harms of
prescribing, should their goal be to lower the risk of fall-related injuries.
We also reported that the duration of medication use was an important concern to balance
medications’ therapeutic effects and side effects. In our study, the continuous use of
antidepressants, drugs for benign prostate hyperplasia, anticholinesterases for
Alzheimer’s disease, emollients for constipation and antithrombin agents was associated
with increased risk of fall-related injury. New initiation of antidepressants, opioids, firstgeneration cephalosporins, non-steroids anti-inflammatory drugs, and laxatives was also
associated with increased risk of fall-related injury. This association between timing of
medication use and fall-related injury provided evidence to clinicians on a time window
for incorporating intensive monitoring and injury prevention strategies. Medication
review has been reported to be effective in preventing fall-related injuries both as a single
intervention (Blalock et al., 2010; Boyé et al., 2016; Sjöberg et al., 2013) or combined as
a component of multifactorial prevention protocols (Matchar et al., 2017; Mikolaizak et
al., 2017; Salimen et al., 2009). But the details on the best way to perform medication
review are still under investigation (American Geriatrics Society, 2019; Huckerby &
Johal, 2015; Jokanovic et al., 2016). Knowledge from Study 3 provided evidence about
the opportune time to perform medication review and which medication classes to focus
on. This knowledge is also of value for older adults and their caregivers, to be more
vigilant during specific times of pharmacotherapy.
Calling back to William Haddon’s injury prevention theory (Haddon, 1980; Sattin, 1992),
this thesis provided evidence for several aspects of injury prevention strategies that
require more focus. For example, reevaluating the necessity for extensive statin use in
older adults, especially in the oldest-old age group; enhancing the importance of
systematic medication review at meaningful time points such as initiation of a new
medication or after a pre-set period of continuous use; expanding the research to explore
the association between medication use and fall-related injuries in different age group, for
different injury types and different duration of medication use; or improving
individualized prescription for older adults.
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According to the definition by the Canadian Institutes for Health Research (CIHR),
knowledge translation is “a dynamic and iterative process that includes synthesis,
dissemination, exchange and ethically-sound application of knowledge to improve the
health of Canadians, provide more effective health services and products and strengthen
the health care system” (CIHR, 2019, “knowledge translation”, para 1). While
conducting studies for this thesis, the author identified that all Canadian drugs databases
use DIN codes and there was no convenient way for quick conversion of DIN codes to
their chemical names and matching ATC codes. For the purpose of this thesis, over 6,600
DINs were converted to 305 ATC 4 th level codes in accordance with Drug Product
Database online query Drug Product Database online query (https://healthproducts.canada.ca/dpd-bdpp/index-eng.jsp) managed by Health Canada. This website
contains detailed information about medication’s generic names, ATC codes, DINs,
dosage, and similar. However, it is burdened with irrelevant information (e.g., approved
but not on market drugs, off-market drugs), which makes conversion between DIN and
ATC very difficult. What is more, the main webpage is not user-friendly because it
contains many search query categories. For a quick reference, direct ATC-DIN or DINATC conversion would be beneficial. With assistance from a professor and students at
the Computer Science department at Western University, we designed an innovative,
user-friendly website for the quick conversion between DINs, ATCs and their chemical
names. We envision users to be researchers analyzing data from Canadian drug
databases, pharmacists across Canada, analysts completing big data extractions and
analysis (e.g., IC/ES, Statistics Canada), students in medical and pharmaceutical schools,
and graduate students comparing published findings in research papers.

5.3

Methodological Considerations and Limitations

It is well-acknowledged that all studies have methodological limitations. The section
below discusses several most important considerations in epidemiological studies in
general and specifically how they were addressed in the studies included in this thesis.
Study 2 and Study 3 were case-control studies. In general, case-control studies begin with
participants who have the outcome of interest (“cases”) and compare them to participants
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who do not have the outcome of interest (“controls”). The case-control studies look
retrospectively to compare how frequently the case and control groups were exposed to a
risk factor and determine the relationship between the risk factor and outcome of interest
(Carlson & Morrison, 2009; Schulz & Grimes, 2002).

5.3.1

Selection of Control Group

Choosing a control group can greatly affect the case-control study’s vulnerability to bias.
Control group should arise from the same general population as the cases, and it should
be similar in every aspect except the outcome of interest (Borgan et al., 2018; Carlson &
Morrison, 2009; Melamed & Robinson, 2019). The case group in our studies included all
older adults who were 66 years and older who had experienced a fall-related injury
between 2010 and 2014. Controls were matched by same age, sex and LHINs (residence
area). Both cases and controls were community-dwelling older adults in Ontario. This
ensured that the control group members represent the population at risk of becoming
cases, independent of the exposure being studied (Schulz & Grimes, 2002). The
imbalance of sex, age group and residence area (LHINs) in our studies can be explained
by the cases and controls not being matched with a fixed ratio. Take age group as an
example (Table 3.1). There were 100,027 cases and 405,127 controls in 66-74 age group,
the ratio of case and control was 1 to 4.05. However, in the 85 years and older group, the
ratio of cases and controls was only 1 to 1.86. That is why there was a higher percentage
of older adults in control group who were 66 to 74 years old than in the case group.

5.3.2

Measurement of exposure information

Exposure history in case-control studies was usually ascertained by interviewing the
participants or analyzing historical medical charts or records. The general concern for
case-control study is that cases will always be more likely to recall past exposures than
controls, which increases recall bias. Interviewers of cases tend to investigate more
thoroughly on exposure history than controls, which is interviewer bias. Exposure history
in our studies (medications prescribed to older adults) was obtained from ODB database.
Every older adult 65 years of age or older in Ontario is automatically entered in ODB
program and this database contains records for every prescription medication filled
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(Government of Ontario, 2019). A study by Levy et al. (2003) reported an overall error
rate of 0.7% (95% CI 0.5% to 0.9%) in ODB database suggesting high coding reliability
and low potential that results of studies using ODB data will be compromised by coding
accuracy. We believe that the information bias in this study was very low.

5.3.3

Precision

The precision is achieved with fewer random errors or random variations present in a
study. Random errors cannot be avoided completely as they are unknown and
unpredictable. Sample selection and measurements of key variables can introduce
random errors (Carlson & Morrison, 2009; Flannelly et al., 2018; Melamed & Robinson,
2019). An effective approach to minimize random errors is to use large sample size so
that the general population can be represented to a larger extent by samples. In this study,
a sample size of over a million individuals was large enough to dilute possible effects of
random errors. Generally speaking, a large sample-sized study with more balanced group
(e.g., similar exposed and unexposed individuals) will produce more precise estimates
(Rothman et al., 2008). Considering that exposure to medications was impossible to be
very high, our study included the most commonly prescribed medication classes as
exposures and thus the precision of the estimates was enhanced. For example, the
exposure rates for statins in case and control group were 21.7% and 13.8%, exposure
rates for biphosphonates in case and control group were 8.2% and 4.4% respectively. We
also used narrow 99%CIs for each estimate of association to enhance precision.

5.3.4

Internal validity

Validity refers to a lack of systematic errors while precision refers to a lack of random
errors. Internal validity describes the extent to which a cause-and-effect established in a
study cannot be explained by other factors. Whether the outcome of interest can be
attributed to the exposure, and not to other causes is the key issue in assessing the internal
validity of a study. A confounding variable is a third variable in a study examining the
cause-and-effect relationship, also known as a confounder or a confounding factor. A
confounding variable may be related to both the dependent (risks) and independent
factors (outcomes). It is very important to address confounding bias in case-control
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studies (Rothman et al., 2008). Usually, this type of bias can be managed in the research
design stage by matching or it can be handled in the analysis stage using analytical
techniques such as stratification or adjustments in logistic regression models (Borgan et
al., 2018; Carlson & Morrison, 2009; Rothman et al., 2008). In this study, we planned
carefully in our DCP to match controls with cases by age, sex and residence area
(LHINs), with a ratio of 1 (cases) to 5 (controls). However, this strict matching protocol
resulted in unavailability of controls in the Ontario RPD database, so we ad justed for
these factors in our multivariate logistic regression model. Neighborhood income quintile
and number of medication classes prescribed were also taken into consideration as
confounding factors. These were carefully chosen based on previous literature (Ek et al.,
2019; Jin et al., 2017; Johnson et al., 2015; Towne et al., 2017). Still, controlling for all
confounding factors is impossible in observational studies (Pearce, 2016; VanderWeele,
2019), thus resulting in residual confounding. The second ary data that comprised the
dataset used in studies of this thesis have been originally collected for other purposes,
such as surveillance of diseases or monitoring the use of public health care resource.
Here, this administrative data was used here to examine novel research questions.
Therefore, a lack of information on confounding factors such as participants’ lifestyles,
environmental factors and comorbidities was inevitable.
Furthermore, research on medications presents its own challenges. On one hand, it is
necessary to understand the specific indications for which the medications were
prescribed, so that the impact of the disease can be separated from the impact of
medication used for the disease. On the other hand, medications were used to treat a
specific disease, so the impact of medications and disease were interwoven with each
other. It is very common that one medication is used for multiple diseases and also that
one disease could be treated with multiple medications. Another important factor
involved in medication treatment that was not adjusted for in this thesis is the drug-drug
interaction. In our population, considerable percentage of older adults were prescribed
multiple medications. The risk of an adverse drug event has been estimated at 13% for
two drugs, 58% for five drugs, and 82% for seven or more drugs (Fulton & Allen, 2005).
It is likely that the increased risk for fall-related injuries might also be related to drugdrug interactions (Bennett et al., 2014). Practically speaking, it is tremendously difficult
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to sort out the singular or combined impact of any specific medication or comorbidity
pairing, especially when we study a wide range of medications. Since we could not fully
address the confounding factors, the results of our studies need to be viewed with caution.

5.3.5

External Validity

External validity, also known as generalizability, is the degree to which the result or
conclusion could be generalized to other places and at other times (Rothman et al., 2008).
In our studies, we included over a million community-dwelling older adults in Ontario.
We believe the study results are generalizable to other places with similar socioeconomic
levels, lifestyles and health care policies, such as other provinces in Canada, Australia
and countries of Western Europe.

5.4

Future Research Directions

The methodological limitations and limitations of results from our studies suggest several
future research directions. First, well-designed prospective cohort studies are required to
provide more convincing results on the association between medications and fall-related
injuries. More research attention is needed to explore medication classes not reported to
be associated to fall-related injuries in previous studies. Second, the definition of
continuous use cannot be generalized. For example, for antihypertensives, use longer than
three-month is considered chronic, while for antibiotics, use longer than two weeks is
considered as chronic. Future research needs to determine a medication-specific
definition of continuous use and identify the optimal time for implementing preventative
strategies for different medication classes. This could also apply to new initiation of
different medications as they have different half-lives. Third, except for duration of
medication use, the dosage of each medication is also important in producing therapeutic
and side effects. Future studies focused on the dosage of different medications and their
association with fall-related injuries are necessary. Fourth, as medications’ impacts and
diseases’ impacts are inextricably bounded up with each other, it is of great importance to
clarify the strength and limitations of whether to separate the impacts of the two or not
and how to make the separation practically and clinically meaningful.

128

5.5

Conclusion

Nearly one third of community dwelling older adults fall every year and almost one third
of the falls result in injuries which require medical consultation or treatment. Total
healthcare system costs of fall-related injuries are high, partly because of the high
incidence, but also due to the high costs per incident. Fortunately, over the past 30 years
of research, many modifiable risk factors have been identified , making the fall-related
injuries in older adults preventable to some extent. However, the complexity of multicomorbidities, latent risk of adverse drug reactions, and poor adherence to
pharmacotherapy in older adults makes it extremely challenging for physicians,
pharmacist and geriatricians in clinical treatment. From the author’s own experience as a
physician, the presence of diseases is something real and medications are necessary to
mitigate the symptoms, improve quality of life and extend life expectancy. When
prescribing medications to older adults, physicians face a dilemma, potentially increase
the risk of fall-related injuries by following clinical best practice guidelines to manage
the disease, or not. With the accumulation of risks, especially in oldest-old, fall-related
injuries have a potential to change lives of older adults and their families, impose
unwelcomed clinical, caregiving and economic consequences. Numerous studies,
guidelines and fall prevention protocols have included lists of fall-risk increasing drugs
and were available both to clinicians and older adults. But, what about medications not
included on the list? Are they safe to use without caution? Based on the findings of three
studies included in this thesis, the answer is no. Our studies offer a comprehensive
description of medications prescribed to older adults prior to fall-related injuries, identify
several medication classes that have not been included on FRIDs lists before, and
demonstrate that both continuous use and new initiation of medications could increase the
risk of fall-related injuries. Results from this thesis provide new evidence for more
medication classes that might be associated with fall-related injuries and require further
attention from both clinicians and researchers. With continued advances in
pharmacotherapy, ever deepening ethical dilemma is: Where are the limits of acceptable
risk when adding new medications to clinical treatments? Growing number of older
adults, exposed to this modifiable risk factor for fall-related injury, are looking for this
answer.
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Appendices
Appendix A List of Fall Risk-Increasing Drugs
Drugs that cause high risk of falling
N02A

Opioids

N05A (excluding Lithium)

Antipsychotics

N05B

Anxiolytics

N05C

Hypnotics and sedatives

N06A

Antidepressants

Drugs that cause orthostatism/hypotension
C01D

Vasodilators used in cardiac diseases (nitrates)

C02

Antihypertensives

C03

Diuretics

C07

Beta-blockers

C08

Calcium channel blockers

C09

Agents acting on the renin-angiotensin system

G04CA

Alpha-adrenoreceptor antagonists

N04B

Dopaminergic agents (anti-Parkinson drugs)

Note adapted from the FRID list by the Swedish National Board of Health and Welfare
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Appendix B: Data Creation Plan for IC/ES
Project Initiation
This Section must be Completed Prior to Project Dataset(s) Creation
Project Title:

The association between selected health indicators, prescription
medications and serious fall-related injuries in older adults (REVISED
July 2019)

Project TRIM number:
Research Program:
Site:
Project Objectives:

DASDAS
ICES WesternICES Western
Insert Project Objectives as listed in the approved ICES Project PIA
The objective of this study is to investigate the association between
selected health indicators, prescription medications and serious fallrelated injuries in older adults
ICES Project PIA Initial
The ICES Employee or agent who is responsible for creating the Project
Approval Date:
Dataset(s) is responsible for ensuring there is an approved ICES
Project PIA and verifying the date of approval prior to creating the
Project Dataset(s)
2017-Jul-12
Principal Investigator (PI): Aleksandra Zecevic
Check the applicable box if ☐ ICES Student
☐ ICES Fellow
☐ ICES Post-Doctoral
the PI is an ICES
Trainee ☐ Visiting Scholar
Student/Trainee
Responsible ICES Scientist: Name the Responsible ICES Scientist if the PI is not a Full Status ICES
Scientist
Project Team Member(s)
Responsible for Project
Dataset Creation and/or
Statistical Analysis and
date joined (list all):

All person(s) (ICES Analyst, Appointed Analyst, Analytic
Epidemiologist, PI, and/or Student) responsible for creating the Project
Dataset(s) and/or statistical analysis on the Research Analytics
Environment (RAE) and the date they joined the project must be
recorded
Aleksandra Zecevic, Yu Ming
2017-Jul-12
Nicolette Lappan
2018-Nov-6
Other ICES Project Team All other Research Project Team Members (e.g., Research
Members and date joined Administrative Assistants, Research Assistants, Project Managers,
(list all):
Epidemiologists) and the date they joined the project must be recorded
yyyy-mon-dd
Confirmation that DCP is The following individuals must confirm that the ICES Data provided for
consistent with Project
in this DCP is relevant (e.g., with respect to cohort, timeframe, and
Objectives:
variables) and required to achieve the Project Objectives stated in the
ICES Project PIA prior to initial Project Dataset creation: 1) PI; 2)
Responsible ICES Scientist if the PI is not a Full Status ICES Scientist,
or a second ICES Scientist or the Scientific Program Lead if the PI is
creating both the DCP and the Project Dataset[s]; 3) ICES Research
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Project Initiation
This Section must be Completed Prior to Project Dataset(s) Creation
and Analysis Staff creating the DCP; and 4) ICES Analytic Staff (ICES
Employee or agent responsible for creating the Project Dataset[s]).
This may be delegated either verbally or via e-mail.
Principal Investigator Aleksandra Zecevic ☐ 2017-Aug-21
Responsible ICES Scientist or Second ICES
☐ yyyy-mon-dd
Scientist/Lead
ICES Research and Analysis Staff Creating
the DCP
☐ yyyy-mon-dd
ICES Analytic Staff
☐ yyyy-mon-dd
Designated ICES Research The person named (ICES staff) is accountable for ensuring that the
and Analysis Staff
approved ICES Project PIA, ICES Project PIA Amendments, and DCP
accountable for Project
are saved on the T Drive, ensuring ICES Project PIA Amendments are
Documentation:
submitted as required, ensuring DCP Amendments are documented, and
sharing the final DCP with the PI/Responsible ICES Scientist at project
completion
DCP Creation Date and
Author:

Date DCP was finalized prior to
Project Dataset(s) creation
Name of person who created the DCP
Date
Name
2017-Aug-20
Yu Ming, Aleksandra Zecevic
2019-Jul-8
Nicolette Lappan
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ICES Data
This Section must be Completed Prior to Project Dataset(s) Creation
The ICES Employee or agent who is responsible for creating the
Project Dataset(s) must ensure that this list includes only data
listed in the ICES Project PIA
Changes to this list after initial ICES Project PIA approval require Mandatory for all datasets that
an ICES Project PIA Amendment
are available by individual year
General Use Datasets – Health Services
Years (where applicable)
See listSee list
See listSee list
General Use Datasets – Care Providers
See listSee list
See listSee list
General Use Datasets – Population
See listSee list
See listSee list
General Use Datasets – Coding/Geography
See listSee list
See listSee list
General Use Datasets - Facilities
See listSee list
General Use Datasets - Other
See listSee list
See listSee list
Controlled Use Datasets
See listSee list
See listSee list
Other Datasets
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Project Amendments and Reconciliation
ICES Project PIA
Privacy approval Person who
Note that any changes to the list of ICES
Amendment History (add date
submitted
Data or Project Objectives require an
additional rows as
amendment
ICES Project PIA Amendment
needed):
Date
Name
Amendment
yyyy-mon-dd
DCP Amendment History
Note that any DCP amendments
(add additional rows as
Person who
involving changes to the list of ICES
needed):
Date DCP
made the DCP Data or Project Objectives require an
amended
amendment
ICES Project PIA Amendment
Date
Name
Amendment
yyyy-mon-dd
Date Programs/DCP
The person(s) creating the dataset and/or analyzing the data are
reconciled
responsible for ensuring that the final DCP reflects the final program(s)
when the project is completed
yyyy-mon-dd

Project Cohort
Study Design

Index Event / Inclusion
Criteria

☒ Cohort study
☐ Matched cohort study
☒
Case-control study
☐ Cross-sectional study
☐ Other (specify):
•
Serious Fall-Related Injuries and Death (Appendix E – ICD-10 W,
S and T codes). When cutting a cohort of cases, please keep information on
all 10 diagnostic codes from NACRS (e.g., dx10code1 – dx10code10), so
we can confirm W code is combined with S or T code (e.g., S and W, T
and W, S&T and W) to make it “fall-related”.
Case group inclusion criteria:
a)
Older adults 65 years and older
b)
Residents of Ontario
c)
Presented to Emergency Department
d)
Diagnosed with a serious fall-related injury or death due to fallrelated injury. Fall-related injury is defined by combining ICD-10 codes for
falls W00-W19 with ICD-10 codes for injuries S00-S99 or T00-T14. The
time between codes W00-W19 and codes S00-S99 or T00-T14 should be
the same day. Descriptive information (e.g., breakdown of S00-S99 or T00T14 and W00-W19 codes) should be included into the dataset to allow
analysis of injury types.)
e)
Diagnosed between Jan 1 2006 and Dec 31 2015.
Control group
a)
Matched to the case group by sex, age Charlson Comorbidity Index
score, and LHIN, with a ratio of 1.5 to 1.
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Project Cohort
b)
Exclude the patients having serious fall-related injuries (codes
W00-W19, codes S00-S99 or T00-14) between Jan 1, 2006 and Dec 31,
2015.
•
The date of visiting Emergency Department due to serious fallrelated injury will be defined as the index event date.
•
For individuals with repetitive serious fall-related injuries during
the observation period, the first time and consecutive visits to ED due to
serious fall-related injury will be taken into account.
Estimated Size of Cohort
(if known)
Exclusions (in order)
Step
1
2
3
4
5
6
7
8

Description
Invalid IKN
Incomplete information (e.g, missing age or missing sex
information, non-Ontario residents, died before ED visits)
<65 years old at the index event date
Patients who have experienced in-hospital serious fall-related
injuries
Excluding diagnoses that are suspected, questionable, rule out.
Excluding transferred ED visits.
Excluding ED visits from which a patient left without being seen.
Excluding scheduled ED visits.

Project Time Frame Definitions
Accrual Window

Look-back Window

Accrual Start/End Dates
Max Follow-up Date
When does observation
window terminate?
Lookback Window(s)

Max Follow-up Date

Observation Window

Index Event Date st

2006 Jan 1 to 2015 December 31st
2017 Jan 1st
12 months after the index date
12 months (till 2005 Jan 1st)

Variable Definitions (add additional rows as needed)
Main Exposure or Risk
For the full list of variables, please refer to Appendix B – Variables
Factor
from NACRS, CIHI-DAD, RAI-HC and ODB.
Primary Outcome
Definition

Serious fall-related injuries (ICD-10 codes W00-W19 combined with
S00-S99 or T00-T14 ICD-10 codes)

144

Variable Definitions (add additional rows as needed)
Secondary Outcome
Death
Definition(s)
Baseline Characteristics
Case and Control: age, sex, Charlson Comorbidity Index score, LHIN
Other Variables
Variables needed from NACRS, CIHI-DAD, RAI-HC and ODB
databases are provided in attached file (Appendix B).
IMPORTANT: to reduce number of observations we decided NOT to
proceed with analysis of OHIP data, hence we excluded it in this
revision.

Analysis Plan and Dummy Tables (expand/modify as needed)
Descriptive Tables (insert or append dummy tables), e.g.: See Appendix C and Appendix D

Quality Assurance Activities
RAE Directory of SAS
Programs
RAE Directory of Final
Dataset(s)

The final analytic dataset for each cohort includes all the data required to create the
baseline tables and run all the models. It should include all covariates for all models
such as patient risk factors, hospital characteristics, physician characteristics,
exposure measures (continuous, categorical) and outcomes. It should include
covariates that were considered but didn’t make the final cut. This would permit an
analyst to easily re-run the models in the future.

RAE README file available:
☐Yes ☐No
Date results of quality assurance tools for final dataset shared
with project team (where applicable):
%assign
yyyy-mon-dd
%evolution

yyyy-mon-dd

%dinexplore

yyyy-mon-dd

%track / %exclude

yyyy-mon-dd

%codebook

yyyy-mon-dd

Additional comments:
Table 1. Baseline characteristics according to primary/secondary exposure
Descriptive statistics, measures of central tendency and dispersion for continuous variables, and
frequency tables for categorical variables. Trends in the data across time will also be analyzed.
Table 2. Outcomes according to primary/secondary exposure: See dummy tables in
Appendix D
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Analysis Plan and Dummy Tables (expand/modify as needed)
Table 3. Covariates (baseline characteristics) according to outcomes: See dummy tables in
Appendix D
Statistical Model(s)
Type of model

Cox Proportional Hazard Regression

Primary independent variable

Risk factors mentioned above

Dependent variable

Serious fall-related injuries and death

Covariates
Sensitivity Analyses

N/A
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Appendix C Ethics Approval
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149
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Appendix D: ICD-10 codes used in this thesis
ICD-10 codes for Injuries and Falls
Falls
W00 Fall on same level involving ice and snow
W01 Fall on same level from slipping, tripping and stumbling
W02 Fall involving skates, skis, sport boards and in-line skates
W03 Other fall on same level due to collision with, or pushing by, another person
W04 Fall while being carried or supported by other persons
W05 Fall involving wheelchair
W06 Fall involving bed
W07 Fall involving chair
W08 Fall involving other furniture
W09 Fall involving swing
W10 Fall on and from stairs and steps
W11 Fall on and from ladder
W12 Fall on and from scaffolding
W13 Fall from, out of or through building or structure
W14 Fall from tree
W15 Fall from cliff
W16 Diving or jumping into water causing injury other than drowning or submersion
W17 Other fall from one level to another
W18 Fall on same level in or from bathtub
W19 Unspecified fall
Injury
S00-S09 Injuries to the head
S10-S19 Injuries to the neck
S20-S29 Injuries to the thorax
S30-S39 Injuries to the abdomen, lower back, lumbar spine and pelvis
S40-S49 Injuries to the shoulder and upper arm
S50-S59 Injuries to the elbow and forearm
S60-S69 Injuries to the wrist and hand
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S70-S79 Injuries to the hip and thigh
S80-S89 Injuries to the knee and lower leg
S90-S99 Injuries to the ankle and foot
T00-T07 Injuries involving multiple body regions
T08-T14 Injuries to unspecified parts of trunk, limb or body region
Fractures
S02 Fracture of skill and facial bones
S12 Fracture of neck
S22 Fracture of rib(s), sternum and thoracic spines
S32 Fracture of lumbar spine and pelvis
S42 Fracture of shoulder and upper arm
S52 Fracture of forearm
S62 Fracture at wrist and hand level
S72 Fracture of femur
S82 Fracture of lower leg, including ankle
S92 Fracture of foot, except ankle
T02 Fractures involving multiple body regions
T08 Fracture of spine, level unspecified
T10 Fracture of upper limb, level unspecified
T12 Fracture of lower limb, level unspecified
T142 Fracture of unspecified body region
Traumatic Brain Injury
S06 intracranial injury
S099 unspecified injury of head
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Appendix E: Anatomical Therapeutic Classifying system
codes and Drug Identification Number
A Drug Identification Number (DIN) is a computer-randomly-generated eight-digit
number assigned by Health Canada to a drug product prior to being marketed in Canada.
It uniquely identifies all drug products sold in a dosage form in Canada and is located on
the label of prescription and over-the-counter drug products that have been evaluated and
authorized for sale in Canada. A DIN uniquely identifies the following product
characteristics: manufacturer; product name; active ingredient(s); strength(s) of active
ingredient(s); pharmaceutical form; route of administration. A DIN lets the user know
that the product has undergone and passed a review of its formulation, labeling and
instructions for use. A drug product sold in Canada without a DIN is not in compliance
with Canadian law (Health Canada, 2018).
The Anatomical Therapeutic Chemical (ATC) Classification is an internationally
accepted classification system for medicines that is maintained by the World Health
Organisation (WHO). It is controlled by the WHO Collaborating Centre for Drug
Statistics Methodology (WHOCC) and was first published in 1976. The WHO assigns
ATC codes to all active substances contained in medicines based on the therapeutic
indication for the medicine. Using the ATC code, active substances are classified in
groups at five different levels according to the organ or system on which they act and
their therapeutic, pharmacological and chemical properties.
The first level of the code indicates the anatomical main group and consists of one letter.
There are 14 main groups.
Code Contents
A

Alimentary tract and metabolism

B

Blood and blood forming organs

C

Cardiovascular system

D

Dermatologicals

G

Genito-urinary system and sex hormones

H

Systemic hormonal preparations, excluding sex hormones and insulins

J

Anti-infectives for systemic use
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L

Antineoplastic and immunomodulating agents

M

Musculo-skeletal system

N

Nervous system

P

Antiparasitic products, insecticides and repellents

R

Respiratory system

S

Sensory organs

V

Various

The second level of the code indicates the therapeutic subgroup and consists of two
digits. The third level of the code indicates the therapeutic/pharmacological subgroup and
consists of one letter. The fourth level of the code indicates the chemical/ therapeutic/
pharmacological subgroup and consists of one letter. The fifth level of the code indicates
the chemical substance and consists of two digits. Take metformin as an example:
Level

Code

Content

1

A

Alimentary tract and metabolism

Anatomical main group

2

A10

Drugs used in diabetes

Therapeutic subgroup

3

A10B

Oral blood glucose lowering drugs

Pharmacological subgroup

4

A10BA

Biguanides

Chemical subgroup

5

A10BA02

Metformin

Chemical substance

Medication information extracted from ODB database are all in DIN codes, so the
conversion of DINs to ATC codes is necessary for better understanding of the result and
easy comparison with other publications.
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Appendix F: Table A1
Table A1
Numbers of Older Adults being Prescribed with Different Medication Classes within One Year Prior to Fall-related Injuries
ATC
Codes
A02BA
A02BB
A02BC
A02BX
A03AB
A03FA
A04AA
A05AA
A06AA
A06AB
A06AC
A06AD
A07AA
A07DA
A07EA
A07EC
A09AA
A10AB

Drug Class
H2-receptor antagonists
Prostaglandins
Proton pump inhibitors
Other drugs for peptic ulcer and
(GORD)
Synthetic anticholinergics,
quaternary ammonium compounds

Propulsives
Serotonin (5HT3) antagonists
Bile acids and derivatives
Softeners, emollients
Contact laxatives
Bulk-forming laxatives
Osmotically acting laxatives
Antibiotics
Antipropulsives
Corticosteroids acting locally
Aminosalicylic acid and similar
agents
Enzyme preparations
Insulins and analogues for
injection, fast-acting

66-74
3180
149
20449

75-84
4049
129
25546

Female
85+
3088
73
19100

313

344

180

837

0.5

143

166

92

401

0.4

1238

0.4

43

34

73

150

0.1

33

38

24

95

0.1

245

0.1

2578
556
101
5198
4250
795
4405
1212
654
3577

3302
378
96
9364
7242
1512
6337
1346
1082
3842

2390
124
48
8785
6522
1414
6058
850
1198
2360

8270
1058
245
23347
18014
3721
16800
3408
2934
9779

4.5
0.6
0.1
12.8
9.9
2.0
9.2
1.9
1.6
5.4

1151
375
38
3480
2811
447
3201
559
391
2007

1443
333
39
5960
4592
953
4336
659
541
2473

823
77
9
4444
3556
816
3049
352
401
1338

3417
785
86
13884
10959
2216
10586
1570
1333
5818

3.2
0.7
0.1
13.1
10.3
2.1
10.0
1.5
1.3
5.5

11687
1843
331
37231
28973
5937
27386
4978
4267
15597

4.1
0.6
0.1
12.9
10.1
2.1
9.5
1.7
1.5
5.4

210

185

80

475

0.3

115

85

37

237

0.2

712

0.2

119

147

103

369

0.2

87

112

41

240

0.2

609

0.2

1503

1126

482

3111

1.7

1494

1112

295

2901

2.7

6012

2.1

Total
10317
351
65095

%
5.7
0.2
35.7

66-74
1762
30
11144

75-84
2309
41
14059

Male
85+
1380
24
8441

Total
Total
5451
95
33644

%
5.1
0.1
31.7

No
15768
446
98739

%
5.5
0.2
34.3
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A10AC
A10AE
A10BA
A10BB
A10BD
A10BF
A10BG
A10BH
A10BX
A11CC
B01AA
B01AB
B01AC
B01AE
B01AF
B01AX
B03AD
B03BA
B03BB
B03XA
B05AA

Insulins and analogues for
injection, intermediate-acting
Insulins and analogues for
injection, long-acting
Biguanides
Sulfonylureas
Combinations of oral blood
glucose lowering drugs
Alpha glucosidase inhibitors
Thiazolidinediones
Dipeptidyl peptidase 4 (DPP-4)
inhibitors
Other blood glucose lowering
drugs, excl. insulins
Vitamin D and analogues
Vitamin K antagonists
Heparin group
Platelet aggregation inhibitors
excl. heparin
Direct thrombin inhibitors
Direct factor Xa inhibitors
Other antithrombotic agents
Iron in combination with folic
acid
Vitamin B12 (cyanocobalamin
and analogues)
Folic acid and derivatives
Other antianemic preparations
Blood substitutes and plasma
protein fractions

615

583

298

1496

0.8

503

505

155

1163

1.1

2659

0.9

1979

1558

627

4164

2.3

1999

1430

426

3855

3.6

8019

2.8

8771
4130

9660
4924

5014
2829

23445
11883

12.9
6.5

7615
3924

7466 2771
4141 1762

17852
9827

16.8
9.3

41297
21710

14.3
7.5

418

304

97

819

0.4

398

232

72

702

0.7

1521

0.5

172
651

191
624

90
200

453
1475

0.2
0.8

142
564

145
495

47
134

334
1193

0.3
1.1

787
2668

0.3
0.9

1779

1697

695

4171

2.3

1650

1339

511

3500

3.3

7671

2.7

43

79

37

159

0.1

28

51

16

95

0.1

254

0.1

499
2280
505

837
5597
537

629
5833
323

1965
13710
1365

1.1
7.5
0.7

458
2643
371

668 395
5344 3576
476 206

1521
11563
1053

1.4
10.9
1.0

3486
25273
2418

1.2
8.8
0.8

2830

5263

5008

13101

7.2

3413

4923 3042

11378

10.7

24479

8.5

317
758
20

884
1037
26

809
714
16

2010
2509
62

1.1
1.4
0.0

381
526
18

560
486
13

1734
1797
54

1.6
1.7
0.1

3744
4306
116

1.3
1.5
0.0

3393

5997

5509

14899

8.2

2075

3733 2846

8654

8.2

23553

8.2

2196

3648

3523

9367

5.1

1119

1986 1559

4664

4.4

14031

4.9

1303
75

1610
141

1091
83

4004
299

2.2
0.2

737
43

890
106

559
63

2186
212

2.1
0.2

6190
511

2.1
0.2

177

348

296

821

0.5

69

128

107

304

0.3

1125

0.4

793
785
23
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B05BB
B05XA
C01AA
C01BC
C01CA
C01DA
C02AB
C02AC
C02CA
C02DB
C03AA
C03BA
C03CA
C03DA
C03DB
C03EA
C04AD
C07AA
C07AB
C07AG
C07BB
C07CA
C08CA

Solutions affecting the
electrolyte balance
Electrolyte solutions
Digitalis glycosides
Antiarrhythmics, class Ic
Adrenergic and dopaminergic
agents
Organic nitrates
Methyldopa
Imidazoline receptor agonists
Alpha-adrenoreceptor
antagonists
Hydrazinophthalazine
derivatives
Thiazides, plain
Sulfonamides, plain
Sulfonamides, plain
Aldosterone antagonists
Other potassium-sparing agents
Low-ceiling diuretics and
potassium-sparing agents
Purine derivatives
Beta blocking agents, nonselective
Beta blocking agents, selective
Alpha and beta blocking agents
Beta blocking agents, selective,
and thiazides
Beta blocking agents, nonselective, and other diuretics
Dihydropyridine derivatives

426

484

245

1155

0.6

318

379

174

871

0.8

2026

0.7

15
779
185

25
2358
245

16
3301
131

56
6438
561

0.0
3.5
0.3

7
892
90

9
9
1812 1525
128
64

25
4229
282

0.0
4.0
0.3

81
10667
843

0.0
3.7
0.3

36

83

32

151

0.1

50

51

209

0.2

360

0.1

3102
60
309

5853
105
217

6997
118
118

15952
283
644

8.8
0.2
0.4

2937
25
82

4645 3545
41
25
71
33

11127
91
186

10.5
0.1
0.2

27079
374
830

9.4
0.1
0.3

221

333

282

836

0.5

451

761

429

1641

1.5

2477

0.9

171

324

277

772

0.4

155

270

129

554

0.5

1326

0.5

9338
1769
5460
1204
629

12533
2527
10254
1821
832

9169
1806
13402
1921
632

31040
6102
29116
4946
2093

17.0
3.4
16.0
2.7
1.1

4603
1148
4101
1055
219

5321 2940
1518 781
7758 6709
1478 957
251 191

12864
3447
18568
3490
661

12.1
3.2
17.5
3.3
0.6

43904
9549
47684
8436
2754

15.2
3.3
16.5
2.9
1.0

1189

1600

1349

4138

2.3

342

468

331

1141

1.1

5279

1.8

114

221

240

575

0.3

142

237

136

515

0.5

1090

0.4

857

1126

884

2867

1.6

545

681

418

1644

1.5

4511

1.6

11055
400

18228
641

15896
521

45179
1562

24.8
0.9

9634
541

12649 7206
821 444

29489
1806

27.8
1.7

74668
3368

25.9
1.2

180

234

128

542

0.3

80

67

35

182

0.2

724

0.3

21

38

29

88

0.0

10

14

9

33

0.0

121

0.0

11153

17993

15951

45097

24.8

7725

9698 5722

23145

21.8

68242

23.7
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C08DA
C08DB
C09AA
C09BA

Phenylalkylamine derivatives
Benzothiazepine derivatives
ACE inhibitors, plain
ACE inhibitors and diuretics
agents acting on the reninangiotensin system
Angiotensin II receptor blockers
(ARBs) and diuretics
ARBs and calcium channel
blockers

240
2993
13192
1985

357
4920
18661
2166

298
4251
15763
1370

895
12164
47616
5521

0.5
6.7
26.1
3.0

144
1870
12529
1604

162
96
2522 1499
15070 8356
1344 581

402
5891
35955
3529

0.4
5.6
33.9
3.3

1297
18055
83571
9050

0.4
6.3
29.0
3.1

9578

13183

9416

32177

17.7

5568

6204 2923

14695

13.8

46872

16.3

3124

3452

2029

8605

4.7

1747

1451

508

3706

3.5

12311

4.3

832

832

451

2115

1.2

471

391

144

1006

0.9

3121

1.1

C10AA

HMG CoA reductase inhibitors

27117

33976

20398

81491

44.7

21800

24490

58194

54.8

139685

48.5

C10AB
C10AC
C10AD
C10AX

Fibrates
Bile acid sequestrants
Nicotinic acid and derivatives
Other lipid modifying agents
HMG CoA reductase inhibitors,
other combinations
Antibiotics
Imidazole and triazole
derivatives
Other antifungals for topical use
Other antipsoriatics for topical
use
Other antibiotics for topical use
Other chemotherapeutics
Corticosteroids, weak (group I)
Corticosteroids, moderately
potent (group II)
Corticosteroids, potent (group
III)

972
437
74
2878

1162
532
65
3148

467
460
14
1170

2601
1429
153
7196

1.4
0.8
0.1
4.0

852
189
132
2601

703
246
90
2442

1190
4
236
157
28
707

1791
592
250
5750

1.7
0.6
0.2
5.4

4392
2021
403
12946

1.5
0.7
0.1
4.5

481

681

442

1604

0.9

442

508

206

1156

1.1

2760

1.0

305

404

393

1102

0.6

150

180

117

447

0.4

1549

0.5

3499

4741

4472

12712

7.0

1862

2453 1767

6082

5.7

18794

6.5

1257

1299

969

3525

1.9

1091

1116

676

2883

2.7

6408

2.2

509

391

198

1098

0.6

444

353

140

937

0.9

2035

0.7

3713
645
3848

5171
620
5128

5205
341
4542

14089
1606
13518

7.7
0.9
7.4

2433
245
2120

3659 2758
275 119
3029 2199

8850
639
7348

8.3
0.6
6.9

22939
2245
20866

8.0
0.8
7.2

971

1099

773

2843

1.6

474

378

1468

1.4

4311

1.5

2290

2734

2014

7038

3.9

1525

2063 1242

4830

4.6

11868

4.1

C09CA
C09DA
C09DB

C10BX
D01AA
D01AC
D01AE
D05AX
D06AX
D06BX
D07AA
D07AB
D07AC

616

158

D07AD
D07XC
D10AF
D10AH
G01AG
G03BA
G03CA
G03HA
G03XA
G03CA
G03HA
G03XA
G04BD
G04CA
G04CB
H02AB
H03AA
H03BA
H04AA
J01AA

Corticosteroids, very potent
(group IV)
Corticosteroids, potent, other
combinations
Antiinfectives for treatment of
acne
Antiinfectives for treatment of
acne

Triazole derivatives
3-oxoandrosten (4) derivatives
Natural and semisynthetic
estrogens, plain
Antiandrogens, plain
Antigonadotropins and similar
agents
Natural and semisynthetic
estrogens, plain
Antiandrogens, plain
Antigonadotropins and similar
agents
Drugs for urinary frequency and
incontinence
Alpha-adrenoreceptor
antagonists
Testosterone-5-alpha reductase
inhibitors
Glucocorticoids
Thyroid hormones
Thiouracils
Glycogenolytic hormones
Tetracyclines

1366

1317

789

3472

1.9

612

754

393

1759

1.7

5231

1.8

200

198

177

575

0.3

121

146

97

364

0.3

939

0.3

58

31

8

97

0.1

43

48

14

105

0.1

202

0.1

79

78

66

223

0.1

49

47

20

116

0.1

339

0.1

195
6

157
4

83
3

435
13

0.2
0.0

N/A
541

N/A
370

N/A
118

N/A
1029

0.0
1.0

440
1042

0.2
0.4

2917

2596

1530

7043

3.9

N/A

N/A

N/A

7

0.0

7050

2.4

2

1

0

3

0.0

31

96

82

209

0.2

212

0.1

482

585

390

1457

0.8

12

10

6

28

0.0

1485

0.5

2917

2596

1530

7043

3.9

N/A

N/A

N/A

7

0.0

7050

2.4

2

1

0

3

0.0

31

96

82

209

0.2

212

0.1

482

585

390

1457

0.8

12

10

6

28

0.0

1485

0.5

2922

4248

3447

10617

5.8

1134

1898 1187

4219

4.0

14836

5.1

841

1051

767

2659

1.5

6362

9975 6452

22789

21.5

25448

8.8

N/A

N/A

N/A

N/A

0.0

3031

4997 3357

11385

10.7

11389

4.0

10186
12594
60
80
309

11888
16233
72
98
288

8114
13300
58
85
190

30188
42127
190
263
787

16.6
23.1
0.1
0.1
0.4

6354
2769
14
72
226

7872 4605
4286 3574
26
8
84
36
240 104

18831
10629
48
192
570

17.7
10.0
0.0
0.2
0.5

49019
52756
238
455
1357

17.0
18.3
0.1
0.2
0.5
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J01CA
J01CF
J01CR
J01DB
J01DC
J01DD
J01EA
J01EE
J01FA
J01FF
J01GB
J01MA
J01XA
J01XD
J01XE
J01XX
J02AB
J02AC
J04AK
J04AM
J05AB
J05AF
J05AH
L01AA
L01AB
L01BA

Penicillins with extended
spectrum
Beta-lactamase resistant
penicillins
Combinations of penicillins,
incl. beta-lactamase inhibitors
First-generation cephalosporins
2nd-generation cephalosporins
3rd-generation cephalosporins
Trimethoprim and derivatives
Intermediate-acting sulfonamides

Macrolides
Lincosamides
Other aminoglycosides
Fluoroquinolones
Glycopeptide antibacterials
Imidazole derivatives
Nitrofuran derivatives
Other antibacterials
Imidazole derivatives
Triazole derivatives
Other drugs for tuberculosis
Combinations of drugs for
treatment of tuberculosis
Nucleosides and nucleotides
Nucleoside and nucleotide
reverse transcriptase inhibitors
Neuraminidase inhibitors
Nitrogen mustard analogues
Alkyl sulfonates
Folic acid analogues

9185

9310

6284

24779

13.6

5536

5849 3128

14513

13.7

39292

13.6

571

669

691

1931

1.1

439

583

379

1401

1.3

3332

1.2

1500

1419

1137

4056

2.2

1024

1038

570

2632

2.5

6688

2.3

18
1764
297
116
2985
8142
1726
14
7489
20
1515
5186
N/A
25
159
16

31
2008
445
213
4057
7044
1740
21
9948
34
1550
7225
N/A
23
144
17

21
1704
379
193
3695
4229
976
11
8864
21
866
5696
N/A
16
78
12

70
5476
1121
522
10737
19415
4442
46
26301
75
3931
18107
14
64
381
45

0.0
3.0
0.6
0.3
5.9
10.7
2.4
0.0
14.4
0.0
2.2
9.9
0.0
0.0
0.2
0.0

15
1037
207
57
1350
4178
973
9
4765
9
872
751
8
42
81
6

15
1343
253
101
1864
4042
970
18
6388
22
860
1310
N/A
39
99
12

13
815
197
65
1217
2096
497
N/A
4268
12
423
1047
N/A
26
41
N/A

43
3195
657
223
4431
10316
2440
31
15421
43
2155
3108
13
107
221
22

0.0
3.0
0.6
0.2
4.2
9.7
2.3
0.0
14.5
0.0
2.0
2.9
0.0
0.1
0.2
0.0

113
8671
1778
745
15168
29731
6882
77
41722
118
6086
21215
27
171
602
67

0.0
3.0
0.6
0.3
5.3
10.3
2.4
0.0
14.5
0.0
2.1
7.4
0.0
0.1
0.2
0.0

33

43

39

115

0.1

22

36

16

74

0.1

189

0.1

887

1001

714

2602

1.4

466

556

272

1294

1.2

3896

1.4

36

12

N/A

52

0.0

64

18

N/A

87

0.1

139

0.0

262
46
108
1047

1017
111
90
1046

2450
56
28
431

3729
213
226
2524

2.0
0.1
0.1
1.4

219
49
33
366

535
89
23
339

778
41
N/A
149

1532
179
56
854

1.4
0.2
0.1
0.8

5261
392
282
3378

1.8
0.1
0.1
1.2
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L01BC
L01XE
L01XX
L02AB
L02AE
L02BA
L02BB
L02BG
L03AA
L04AA
L04AB
L04AD
L04AX
M01AE
M01AH
M03BX
M04AA
M05BA
M05BX
N02AA
N02AB
N02AJ
N02BA
N03AA
N03AB
N03AE

Pyrimidine analogues
Protein kinase inhibitors
Other antineoplastic agents
Progestogens
Gonadotropin releasing
hormone analogues
Anti-estrogens
Anti-androgens
Aromatase inhibitors
Colony stimulating factors
Selective immunosuppressants
Tumor necrosis factor alpha
(TNF-α) inhibitors
Calcineurin inhibitors
Other immunosuppressants
Propionic acid derivatives
Coxibs
Other centrally acting agents
Preparations inhibiting uric acid
production
Biphosphonates
Other drugs affecting bone
structure and mineralization
Natural opium alkaloids
Phenylpiperidine derivatives
Opioids in combination with
non-opioid analgesics
Salicylic acid and derivatives
Barbiturates and derivatives
Hydantoin derivatives
Benzodiazepine derivatives

63
43
75
52

83
48
156
100

14
12
147
107

160
103
378
259

0.1
0.1
0.2
0.1

31
37
52
60

N/A

N/A

N/A

N/A

0.0

243
N/A
978
98
240

291
N/A
971
45
175

230
N/A
514
15
46

764
N/A
2463
158
461

108

90

28

270
189
4491
3717
1119

169
139
3622
3891
850

1240

46
39
91
110

20
14
64
68

97
90
207
238

0.1
0.1
0.2
0.2

257
193
585
497

0.1
0.1
0.2
0.2

487

1269 1087

2843

2.7

2844

1.0

0.4
0.0
1.4
0.1
0.3

10
225
N/A
31
202

30
684
N/A
26
105

30
675
N/A
6
15

70
1584
10
63
322

0.1
1.5
0.0
0.1
0.3

834
1586
2473
221
783

0.3
0.6
0.9
0.1
0.3

226

0.1

33

23

N/A

56

0.1

282

0.1

97
62
1766
2288
306

536
390
9879
9896
2275

0.3
0.2
5.4
5.4
1.2

203
101
2570
1698
566

160
91
1973
1729
412

62
24
748
778
135

425
216
5291
4205
1113

0.4
0.2
5.0
4.0
1.0

961
606
15170
14101
3388

0.3
0.2
5.3
4.9
1.2

2250

1920

5410

3.0

2683

3815 2010

8508

8.0

13918

4.8

14187

21354

15912

51453

28.2

1867

3299 2316

7482

7.1

58935

20.4

446

896

679

2021

1.1

14

28

77

0.1

2098

0.7

15408
608

17873
922

12311
877

45592
2407

25.0
1.3

10350
334

10711 5437
407 237

26498
978

25.0
0.9

72090
3385

25.0
1.2

13685

15531

10035

39251

21.6

9283

9555 4712

23550

22.2

62801

21.8

1351
164
716
2372

2294
172
710
1967

1931
89
437
1049

5576
425
1863
5388

3.1
0.2
1.0
3.0

1239
134
713
1060

1785 1078
133
58
666 311
916 369

4102
325
1690
2345

3.9
0.3
1.6
2.2

9678
750
3553
7733

3.4
0.3
1.2
2.7

35
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N03AF
N03AG
N03AX
N04AA
N04BA
N04BB
N04BC
N04BD
N04BX
N05AA
N05AB
N05AC
N05AD
N05AH
N05AN
N05AX
N05BA
N05CD
N06AA
N06AB
N06AG
N06AX
N06BA
N06DA
N07AA
N07AB

Carboxamide derivatives
Fatty acid derivatives
Other antiepileptics
Tertiary amines
Dopa and dopa derivatives
Adamantane derivatives
Dopamine agonists
Monoamine oxidaseB inhibitors

Other dopaminergic agents
Phenothiazines-aliphatic sidechain
Phenothiazines piperazine structure
Phenothiazines piperidine structure
Butyrophenone derivatives
Diazepines, oxazepines,
thiazepines and oxepines
Lithium
Other antipsychotics
Benzodiazepine derivatives
Benzodiazepine derivatives
Non-selective monoamine
reuptake inhibitors
Selective serotonin reuptake
inhibitors
Monoamine oxidase A
inhibitors
Other antidepressants
Centrally acting
sympathomimetics
Anticholinesterases
Anticholinesterases
Choline esters

538
603
3036
64
924
102
742
24
91
168
899
79
182

491
340
3026
47
1653
74
719
29
119
111
855
98
349

284
153
1889
21
1001
16
400
14
39
75
373
52
416

1313
1096
7951
132
3578
192
1861
67
249
354
2127
229
947

0.7
0.6
4.4
0.1
2.0
0.1
1.0
0.0
0.1
0.2
1.2
0.1
0.5

377
432
1638
65
1023
97
455
38
117
124
537
24
179

308
278
1656
49
1971
103
514
37
176
102
487
15
319

130
90
757
6
860
13
189
11
48
56
160
7
222

815
800
4051
120
3854
213
1158
86
341
282
1184
46
720

0.8
0.8
3.8
0.1
3.6
0.2
1.1
0.1
0.3
0.3
1.1
0.0
0.7

2128
1896
12002
252
7432
405
3019
153
590
636
3311
275
1667

0.7
0.7
4.2
0.1
2.6
0.1
1.0
0.1
0.2
0.2
1.1
0.1
0.6

2178

3160

3404

8742

4.8

1431

1993 1413

4837

4.6

13579

4.7

295
778
10302
1207

194
1585
13766
1537

78
2049
10602
1184

567
4412
34670
3928

0.3
2.4
19.0
2.2

187
562
4420
656

97
18
958 789
5446 3334
808 515

302
2309
13200
1979

0.3
2.2
12.4
1.9

869
6721
47870
5907

0.3
2.3
16.6
2.0

4182

4347

2208

10737

5.9

1452

1437

695

3584

3.4

14321

5.0

9510

11206

9084

29800

16.4

4198

5191 3221

12610

11.9

42410

14.7

50

41

12

103

0.1

28

7

59

0.1

162

0.1

7940

8789

7339

24068

13.2

3806

4399 2873

11078

10.4

35146

12.2

145

99

72

316

0.2

104

32

224

0.2

540

0.2

1295
47
48

6300
47
57

7831
29
46

15426
123
151

8.5
0.1
0.1

997
30
28

3746 3319
50
25
53
44

8062
105
125

7.6
0.1
0.1

23488
228
276

8.1
0.1
0.1

24

88
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N07BA
P03AC
R01AD
R02AX
R03BA
R03BB
R03CB
R03CC
S01AA
S01AD
S01AE
S01BA
S01BC
S01EA
S01EB
S01EC
S01ED
S01EE
S01FA
S01GX
S01HA
S01LA
S02CA
V06DC

Drugs used in nicotine dependence

Pyrethrines
Corticosteroids (nasal preparations)
Other nasal preparations
Glucocorticoids (drugs for COPD)
Anticholinergics
Non-selective betaadrenoreceptor agonists
Selective beta-2-adrenoreceptor
agonists
Antibiotics-ophthalmologicals
Antivirals-ophthalmologicals
Fluoroquinolones
Corticosteroids, plain
Antiinflammatory agents,
Sympathomimetics in glaucoma
Parasympathomimetics
Carbonic anhydrase inhibitors
Beta blocking agents
Prostaglandin analogues
Anticholinergics
Other antiallergics
Local anesthetics
Antineovascularisation agents
Corticosteroids and antiinfectives (otologicals)
Carbohydrates

237
90
3002
32
4821
4553

48
141
2786
33
4940
6158

N/A
217
1547
21
3189
4246

288
448
7335
86
12950
14957

0.2
0.2
4.0
0.0
7.1
8.2

196
63
1577
21
2184
3341

77

84

79

240

0.1

44

9090

9039

6065

24194

13.3

2063
68
76
3520
1240
707
71
1022
909
2491
162
792
139
318

2660
61
100
4958
1800
1336
152
1975
1681
4673
198
988
98
1107

2028
45
96
2405
811
1315
251
2204
1946
5003
177
591
58
1530

6751
174
272
10883
3851
3358
474
5201
4536
12167
537
2371
295
2955

421

487

266

9727

11013

5692

43 N/A
82
77
1726 876
19
7
2743 1522
5164 3197

240
222
4179
47
6449
11702

0.2
0.2
3.9
0.0
6.1
11.0

528
670
11514
133
19399
26659

0.2
0.2
4.0
0.0
6.7
9.2

34

118

0.1

358

0.1

4754

5607 3227

13588

12.8

37782

13.1

3.7
0.1
0.1
6.0
2.1
1.8
0.3
2.9
2.5
6.7
0.3
1.3
0.2
1.6

1127
45
43
1919
694
496
46
677
503
1475
172
321
110
241

1658
53
63
2855
1121
945
83
1377
1002
2805
214
404
89
620

1080
36
63
1334
460
669
98
1031
820
2221
126
235
27
638

3865
134
169
6108
2275
2110
227
3085
2325
6501
512
960
226
1499

3.6
0.1
0.2
5.8
2.1
2.0
0.2
2.9
2.2
6.1
0.5
0.9
0.2
1.4

10616
308
441
16991
6126
5468
701
8286
6861
18668
1049
3331
521
4454

3.7
0.1
0.2
5.9
2.1
1.9
0.2
2.9
2.4
6.5
0.4
1.2
0.2
1.5

1174

0.6

253

308

171

732

0.7

1906

0.7

26432

14.5

7991

8510 3329

19830

18.7

46262

16.0

40

Note. Medication classes that were prescribed to less than six persons were reported as N/A to protect the patients’ privacy
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